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1. Introduction 
This report describes and summarises results 
of the twenty-fifth proficiency test trial 
conducted by the National Food Institute (DTU 
Food) as the EU Reference Laboratory for 
Antimicrobial Resistance (EURL-AR). This 
proficiency test focuses on antimicrobial 
susceptibility testing (AST) of Salmonella and 
Campylobacter and is the twelfth External 
Quality Assurance System (EQAS) conducted 
for these microorganisms (the first was EQAS 
2006). In addition, the proficiency test includes 
categorisation of the relevant Salmonella 
strains as presumptive ESBL-, AmpC- and 
carbapenemase-producing organisms, and 
identification of the Campylobacter species as 
either C. jejuni or C. coli. 
In addition, for the tenth time, an optional 
element was included, consisting of genotypic 
characterisation of antimicrobial resistance 
genes by PCR and/or sequencing. This optional 
component included characterisation of genes 
encoding ESBL-, AmpC- and carbapenemases 
in the Salmonella test strains. 
This EQAS aims to: i) monitor the quality of 
AST results produced by National Reference 
Laboratories (NRL-AR), ii) identify laboratories 
which may need assistance to improve their 
performance in AST, and iii) determine possible 
topics for further research or collaboration. 
In reading this report, the following important 
considerations should be taken into account: 
1) Expected results were generated by 
performing Minimum Inhibitory Concentration 
(MIC) determinations for all test strains in two 
different occasions at the Technical University 
of Denmark, National Food Institute (DTU 
Food). These results were then verified by the 
Centers for Disease Control and Prevention, 
Georgia, US (Salmonella) and the United 
States Food and Drug Administration (FDA), 
Centre for Veterinary Medicine, Maryland, US 
(Salmonella and Campylobacter). Finally, a MIC 
determination was performed at DTU Food after 
preparation of the agar stab culture/charcoal 
swab for shipment to participants to confirm that 
the vials contained the correct strains with the 
expected MIC values. 
2) Evaluation is based on interpretations of 
AST values determined by the participants. This 
is in agreement with the method used by 
Member States (MS) to report AST data to the 
European Food Safety Authority (EFSA), and 
complies with the main objective of this EQAS, 
i.e. to evaluate and improve the comparability of 
surveillance data on antimicrobial susceptibility 
of Salmonella and Campylobacter reported to 
EFSA by different laboratories, as stated in the 
protocol. 
3) The EURL-AR network agreed on setting the 
acceptable deviation level for laboratory 
performance on AST to 5%. For the optional 
genotypic characterisation, no specific 
acceptance level has been set. 
Evaluation of a result as “deviating from the 
expected interpretation” should be carefully 
analyzed in a self-evaluation procedure 
performed by the participant including also 
considerations related to any corrective actions 
introduced in the laboratory. Note that it is not 
considered a mistake to obtain a one-fold 
dilution difference in the MIC of a specific 
antimicrobial when testing the same strains 
since methods used for MIC determination have 
limitations. If, however, the expected MIC is 
close to the breakpoint value for categorising 
the strain as susceptible or resistant, a one-fold 
dilution difference - which is acceptable - may 
result in two different interpretations, i.e. the 
same strain can be categorised as susceptible 
or resistant. This result may be evaluated as 
correct based on the MIC-value produced but 
incorrect when the evaluation is based on the 
interpretation of the MIC value. This report is 
based on evaluation of AST interpretations, 
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therefore some participants may find their 
results classified as incorrect even though the 
actual MIC they reported is only a one-fold 
dilution away from the expected MIC. In these 
cases, the participants should be confident 
about the good quality of their performance of 
AST by MIC. In the organization of the EQAS, 
we try to avoid these situations by choosing test 
strains with MIC values distant from the cut offs 
for resistance, which is not always feasible for 
all strains and all antimicrobials. Therefore, the 
EURL-AR network unanimously established in 
2008 that if there are less than 75% correct 
results for a specific strain/antimicrobial 
combination, the reasons for this situation must 
be further examined and, on selected occasions 
explained in details case by case, these results 
may subsequently be omitted from the 
evaluation report.  
This report is approved in its final version by a 
technical advisory group composed by 
competent representatives from all NRL-ARs. 
This group meets annually at the EURL-AR 
workshop. 
All conclusions presented in this report are 
publically available. Participating laboratories 
are identified by codes and each code is known 
only by the corresponding laboratory. The full 
list of laboratory codes is confidential and 
known only by relevant representatives of the 
EURL-AR and the EU Commission.  
The EURL-AR is accredited by DANAK as 
provider of proficiency testing (accreditation no. 
516); working with zoonotic pathogens and 
indicator organisms as bacterial isolates 
(identification, serotyping and antimicrobial 
susceptibility testing). 
2. Materials and Methods  
2.1 Participants in EQAS 2018 
A pre-notification (Appendix 1) to announce the 
EURL-AR EQAS on AST of Salmonella and 
Campylobacter was distributed on the 28th  
August 2018 by e-mail to the 45 laboratories in 
the EURL-AR-network including all EU 
countries and Iceland, North Macedonia, 
Norway, Serbia, Switzerland and Turkey. All EU 
MS as well as Iceland, Norway, and Switzerland 
were represented as participants for both 
Salmonella and Campylobacter. FYROM was 
represented as a participant for Salmonella. In 
addition to the AST of Salmonella and 
Campylobacter, an optional genotypic 
characterisation by PCR/sequencing of 
antimicrobial resistance genes of the ESBL-, 
AmpC- and carbapenemase-producing 
Salmonella test strains was offered. Eleven 
laboratories participated in the optional 
genotypic characterisation of the ESBL-, AmpC- 
and carbapenemase-producing Salmonella test 
strains (see Appendix 2). 
In addition to the MS NRLs, six additional 
laboratories were included as participants in the 
EQAS; one from each of the following 
countries: North Macedonia, Iceland, the 
Netherlands, Norway, Spain, and Switzerland. 
These were invited to take part in the EQAS 
2018 on the basis of their participation in 
previous EQAS iterations and/or affiliation to 
the EU network. These laboratories were 
charged a fee for their participation in the 
EQAS, whereas the NRLs from EU Member 
States participated free of charge. 
The results evaluated and presented in this 
report (N=32; Appendix 2) are from the NRLs 
designated by the MS (n=29) and NRLs in 
affiliated non-MS (n=4) (North Macedonia, 
Iceland, Norway, and Switzerland). Figure 1 
illustrates the 32 participating countries.  
In total, this report evaluates 32 sets of results 
from the Salmonella AST component, 31 sets of 
results from the Campylobacter AST 
component and eleven sets of results in relation 
to the optional genotypic characterisation.  
The 25th EURL-AR Proficiency Test Salmonella, Campylobacter and genotypic characterisation (2018), final version, 1 ed.
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Figure 1: Participating countries that performed antimicrobial susceptibility testing of Salmonella 
and Campylobacter in 2018. 
Results from the laboratories not designated by 
the MS but enrolled in the EQAS are not further 
presented or evaluated in this report. 
2.2 Strains  
Eight Salmonella strains and eight 
Campylobacter strains were selected for this 
trial among isolates from the strain collection at 
DTU Food on the basis of antimicrobial 
resistance profiles and MIC values. For quality 
assurance purposes, one strain per bacterial 
species has been included in all EQAS 
iterations performed to date, representing an 
internal control. 
Prior to distribution of the strains, DTU Food 
performed AST on the Salmonella and 
Campylobacter strains and the AST profiles 
were verified by the Centers for Disease 
Control and Prevention (CDC), Georgia, US 
(Salmonella) and the United States Food and 
Drug Administration (FDA), Centre for 
Veterinary Medicine, Maryland, US (Salmonella 
and Campylobacter). When MIC-values were 
not in agreement but varied +/- one dilution-
step, the value obtained by DTU Food was 
selected as the reference value. The obtained 
MIC values served as reference for the test 
strains (Appendix 3a and 3b). Results for the 
following antimicrobials were not verified by 
CDC or FDA for Salmonella: cefepime, 
cefotaxime, cefotaxime/clavulanic acid, 
ceftazidime, ceftazidime/clavulanic acid, 
colistin, ertapenem, imipenem, temocillin, 
tigecycline and trimethoprim, and results for the 
following antimicrobials were not verified by 
FDA  for Campylobacter: streptomycin. 
Reference strains Escherichia coli CCM 3954 
(ATCC 25922) and Campylobacter jejuni CCM 
6214 (ATCC 33560) had been forwarded to all 
participating laboratories when they were new 
participants with instructions to store and 
maintain them for quality assurance purposes 
The 25th EURL-AR Proficiency Test Salmonella, Campylobacter and genotypic characterisation (2018), final version, 1 ed.
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and future EQAS trials. Moreover, the EURL-
AR has distributed Campylobacter coli (2012-
70-443-2) and Acinetobacter baumannii (2012-
70-100-69) for the purpose of performing 
internal control of the method. 
2.3 Antimicrobials  
The antimicrobials tested in this EQAS are 
listed in the protocol (Appendix 4b).  
The antimicrobials tested correspond to the 
panel of antimicrobials listed in Decision 
2013/652/EU.  
The method applied for the AST was the ISO 
standard, ISO 20776-1 “Clinical laboratory 
testing and in vitro diagnostic test system – 
Susceptibility testing of infectious agents and 
evaluation of performance of antimicrobial 
susceptibility test devices”, and, in addition, the 
following guidelines/standards from the Clinical 
and Laboratory Standards Institute (CLSI) were 
applied: Document M7-A11 (2018) “Methods for 
Dilution Antimicrobial Susceptibility Tests for 
Bacteria That Grow Aerobically; Eleventh 
Edition”; document M100, 28th ed. (2018) 
“Performance Standards for Antimicrobial 
Susceptibility Testing”, document VET01 (2018) 
“Performance Standards for Antimicrobial Disk 
and Dilution Susceptibility Tests for Bacteria 
Isolated From Animals” – Fifth Edition; and 
document VET06 (2017) “Methods for 
Antimicrobial Susceptibility Testing of 
Infrequently Isolated or Fastidious Bacteria 
Isolated from Animals” – First Edition. 
MIC results were interpreted by using the 
interpretative criteria listed in Decision 
2013/652/EU. Where cut-off values were not 
available, the list of interpretative criteria was 
supplemented either with CLSI-interpretative 
criteria or with tentative values as described in 
the protocol (Appendix 4). No interpretative 
criteria were available for cefepime. Results for 
presumptive beta-lactam resistance 
mechanisms were interpreted according to the 
most recent EFSA recommendations also 
included as an appendix in the EQAS protocol 
(Appendix 4).  
The selection of antimicrobials used in the trial 
for Salmonella were: ampicillin (AMP), 
azithromycin (AZI), cefepime (FEP), cefotaxime 
(FOT), cefotaxime/clavulanic acid (FOT/Cl), 
cefoxitin (FOX), ceftazidime (TAZ), 
ceftazidime/clavulanic acid (TAZ/Cl), 
chloramphenicol (CHL), ciprofloxacin (CIP), 
colistin (COL), ertapenem (ERT), gentamicin 
(GEN), imipenem (IMI), meropenem (MER), 
nalidixic acid (NAL), sulfonamides 
(sulfamethoxazole) (SMX), tetracycline (TET), 
tigecycline (TGC), temocillin (TRM) and 
trimethoprim (TMP).  
Minimum Inhibitory Concentration (MIC) 
determination of the Salmonella test strains was 
performed using the Sensititre system 
(EUVSEC and EUVSEC2) from Trek Diagnostic 
Systems Ltd, UK.  
For Campylobacter the following antimicrobials 
were included: ciprofloxacin (CIP), erythromycin 
(ERY), gentamicin (GEN), nalidixic acid (NAL), 
streptomycin (STR), and tetracycline (TET).  
MIC determination for the Campylobacter 
testing was performed using the Sensititre 
systems (EUCAMP2) from Trek Diagnostic 
Systems Ltd, UK. Participants of the 
Campylobacter EQAS were additionally 
requested to identify the species of the 
Campylobacter spp. as either C. jejuni or C. 
coli. 
2.4 Distribution 
On 16 October 2018, bacterial strains in agar 
stab cultures (Salmonella spp.) or charcoal 
swabs in transport media (Stuarts) 
(Campylobacter spp.) together with a welcome 
letter (Appendix 4a) were dispatched in double 
pack containers (class UN 6.2) to the 
participating laboratories. The shipment 
(UN3373, biological substances category B) 
was sent according to International Air 
Transport Association (IATA) regulations.  
The 25th EURL-AR Proficiency Test Salmonella, Campylobacter and genotypic characterisation (2018), final version, 1 ed.
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2.5 Procedure 
Protocols and all relevant information were 
uploaded on the EURL-AR website 
(http://www.eurl-ar.eu). thereby EQAS 
participants could access necessary information 
at any time.  
Participants were instructed to subculture 
charcoal swabs immediately and store the agar 
stabs at 4ºC (dark) until performance of AST. 
Information related to the handling of the test 
strains and reference strains (Appendix 4b, c, d, 
e) was made available.  
The participants were instructed to apply the 
interpretative criteria listed in the protocol 
(Appendix 4). Instructions for interpretation of 
AST results allowed for categorisation of strains 
as resistant or susceptible. Categorisation as 
‘intermediate’ was not accepted.  
The EURL-AR is aware that there are two 
different types of interpretative criteria of 
results, i.e clinical breakpoints and 
epidemiological cut-off values. The terms 
‘susceptible’, ‘intermediate’ and ‘resistant’ 
should be reserved for classifications made in 
relation to the therapeutic application of 
antimicrobial agents. When reporting data using 
epidemiological cut-off values, bacteria should 
be reported as ‘wild-type’ or ‘non-wild-type’ 
(Schwarz et al., 2010). To simplify the 
interpretation of results, throughout this report, 
we will maintain the terms susceptible and 
resistant, even if referring to wild-type and non-
wild-type strains, respectively. 
As regards the method for performing the 
antimicrobial susceptibility testing, the protocol 
referred to Decision 2013/652/EU and 
instructed participants to perform the 
international reference method for antimicrobial 
susceptibility testing. I.e. dilution methods 
performed according to the methods described 
by the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) and the 
Clinical and Laboratory Standards Institute 
(CLSI), accepted as the international reference 
method (ISO standard 20776-1:2006).  
A mandatory part of the proficiency test was to 
detect ESBL-, AmpC- and carbapenemase-
producing strains and interpret results 
according to the most recent EFSA 
recommendations as described in the protocol.  
Results for QC reference strains were MIC 
values for the reference strains E. coli (ATCC 
25922) and C. jejuni (ATCC 33560). The results 
were evaluated towards the quality control 
ranges according to the relevant guidelines; i.e. 
the CLSI documents VET06 (2017) or M100S, 
28th ed. (2018) (Appendix 5). 
For the optional genotypic characterisation of 
the genetic basis for resistance to extended-
spectrum cephalosporins and carbapenems in 
the Salmonella test strains, participating 
laboratories were invited to report the genes. 
For the test strains included in this component 
of the EQAS, the organizers, decided to include 
blaTEM-1 (encoding TEM-beta-lactamases) as an 
expected gene. The genes listed in the table in 
the protocol (Appendix 4b) were included in the 
test. Identification of additional genes not listed 
in the protocol was not evaluated by the 
database. The results were evaluated based on 
the identified genes and variants. 
The participating laboratories were encouraged 
to use their own laboratory’s method(s) for the 
genotypic characterisation. The expected 
results for this component of the EQAS were 
obtained by whole-genome-sequencing and 
subsequent analysis using the ResFinder 3.0 
platform available at 
http://cge.cbs.dtu.dk/services/ResFinder/. The 
positive identification of genes was not verified 
elsewhere. 
All participating laboratories were invited to 
enter the obtained results into an electronic 
record sheet at the EURL-AR web-based 
database through a secured individual login and 
password.  
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In addition, participants were encouraged to 
complete an evaluation form available at the 
EURL-AR database with the aim to improve 
future EQAS trials. 
The database was finally closed and 
evaluations were made available to participants 
on February 7, 2019. After this date, the 
participants were invited to login to retrieve an 
individual, database-generated report which 
contained an evaluation of the submitted results 
including possible deviations from the expected 
interpretations. Deviations in interpretation 
(resistant or susceptible) were categorised as 
‘incorrect’, as were also deviations concerning 
confirmation of an isolate as extended spectrum 
beta-lactamase- (ESBL-), AmpC- or 
carbapenemase-producer. 
3. Results 
The participants were asked to report results, 
i.e. MIC values and the categorisation as 
resistant or susceptible. Only the categorisation 
was evaluated, whereas the MIC values were 
used as supplementary information. 
3.1 Data omitted from the report 
As mentioned in the introduction, the EURL-AR 
network established that data should be 
examined and possibly omitted from the 
general analysis if there are less than 75% 
correct results based on strain/antimicrobial 
combination (see Appendix 7a and 7b for an 
overview of correct/incorrect results). In the 
present EQAS this occurred in two cases which 
have been examined and consequently omitted 
from the analysis; 1) S-13.1/ceftazidime 
(expected interpretation was ‘resistant’, 
however, 37% of the submitted results (from 15 
laboratories) found the strain susceptible in 
either panel 1 or panel 2. All but two of the 
deviating interpretations were based on MIC 
values one step from the expected; 2) S-
13.7/cefoxitin (expected interpretation was 
‘susceptible’), however, 35% found the strain 
resistant to cefoxitin. All of the deviating 
interpretations were based on MIC values 
within one step from the expected. 
For Campylobacter, no problems specific for a 
strain/antimicrobial-combination were identified. 
3.2 Methods  
Results obtained by broth microdilution were 
accepted and evaluated. For both the 
Salmonella and the Campylobacter trial, all 32 
and 31 laboratories, respectively, reported 
results obtained by broth microdilution. 
With the aim to conclude on the strains’ 
presumptive ESBL-, AmpC- and 
carbapenemase phenotype, two panels of 
antimicrobials were included in the testing of 
the Salmonella strains as also specified in the 
EU regulation 2013/652/EU. The test strains 
found resistant to cefotaxime, ceftazidime or 
meropenem on the first panel (see 
2013/652/EU, Table 1) were additionally tested 
on the second panel (see 2013/652/EU, Table 
4) according to the protocol indications.  
3.3 Deviations, overall 
The list of deviations is presented in Appendix 
8a and 8b. Figure 2 shows the total percentage 
of deviations from the expected results of AST 
performed by participating laboratories. Overall, 
the deviation levels in 2018 are acceptable for 
both the Salmonella and the Campylobacter 
trials. 
The internal control strains mainly followed the 
trend in deviation level of the different EQAS 
trials (Figure 2). 
3.3.1 Salmonella trial  
For the Salmonella strains, 99.0% of the AST 
results were correct. The number of AST’s 
performed and the percentage of correct results 
for the individual strains in the EQAS, are listed 
The 25th EURL-AR Proficiency Test Salmonella, Campylobacter and genotypic characterisation (2018), final version, 1 ed.
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Figure 2: A comparison between the EURL-AR EQAS’s since 2006, showing the total percentage of 
deviations for antimicrobial susceptibility testing performed by participating laboratories.  
in Table 1. Variations of obtained correct results 
ranged from 96.3 to 99.8%. Table 2 illustrates 
the percentage of correct AST per antimicrobial 
by bacterial species. The level of correct AST 
was at 94.5% (cefoxitin) or above, for all the 
Salmonella test strains. For cefoxitin, four of the 
seven deviations could be attributed to one 
laboratory (#19) for which all incorrect 
interpretations were based on an obtained MIC 
value that was equal to the expected MIC value 
which was incorrectly interpreted as resistant.  
ESBL/AmpC/carbapenemase-producing 
Salmonella test strains 
Confirmation of beta-lactamase production is a 
mandatory component of this EQAS.  
According to the protocol, which was based on 
the EFSA recommendations, the confirmatory 
test for ESBL-, AmpC-, and carbapenemase-
producing isolates requires use of both 
cefotaxime (FOT) and ceftazidime (TAZ) alone 
and in combination with a β-lactamase inhibitor. 
The MIC value for either antimicrobial agent 
(FOT or TAZ) tested in combination with 
clavulanic acid should be compared to the 
corresponding MIC when tested alone. Synergy 
is defined for one or both cephalosporins if a  
≥ 3-dilution-step difference is observed between 
the two MIC values (i.e. if the FOT:CTX/Cl or 
TAZ:TAZ/Cl ratio ≥8) (CLSI M100S Table 2A; 
Enterobacteriaceae). Participants were 
instructed to test strains to use the second 
panel of antimicrobials to test strains presenting 
resistance to cefotaxime (FOT), ceftazidime 
(TAZ or meropenem (MERO) on panel 1. 
The classification of the phenotypic results was 
based on the most recent EFSA 
recommendations as indicated in the protocol 
(Appendix 4). 
In this EQAS, all laboratories uploaded results 
for the strains to be tested on panel 2. 
Table 3 presents that the strains S-13.1, S-13.4, 
S-13.7 and S-13.8 were ESBL producers, and 
strain S-13.6 was a carbapenemase producer. 
For strain S-13.7, some laboratories (34%) 
obtained an MIC value for cefoxitin at 16 and 
consequently reported a categorisation as 
‘resistant’. As mentioned above in paragraph 
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Table 1. The number of AST performed and the percentage of correct results for each strain of Salmonella (panel 1 
and panel 2) and Campylobacter. 
EQAS 2018 – Salmonella  EQAS 2018 – Campylobacter 
Test strain AST in total % correct  Test strain AST in total % correct 
S-13.1 590 99.8  C-13.1 (C. jejuni) 186 98.9 
S-13.2 445 99.8  C-13.2 (C. coli) 186 99.5 
S-13.3 448 99.1  C-13.3 (C. coli) 180 98.9 
S-13.4 655 99.2  C-13.4 (C. jejuni) 186 100.0 
S-13.5 447 98.9  C-13.5 (C. jejuni) 186 100.0 
S-13.6 650 96.3  C-13.6 (C. jejuni) 184 98.4 
S-13.7 623 99.7  C-13.7 (C. coli) 186 100.0 
S-13.8 655 99.5  C-13.8 (C. jejuni) 186 100.0 
 
Table 2: Percentage of correct antimicrobial 
susceptibility tests per antimicrobial by 
microorganism.  
Antimicrobial Salmonella Campylobacter 
Ampicillin 99.6 - 
Azithromycin 99.5 - 
Cefotaxime 98.3 - 
Cefoxitin 94.5 - 
Ceftazidime 99.4 - 
Chloramphenicol 99.6 - 
Ciprofloxacin 98.8 99.6 
Colistin 98.8 - 
Ertapenem 99.4 - 
Erythromycin - 99.2 
Gentamicin 100.0 100.0 
Imipenem 96.9 - 
Meropenem 98.8 - 
Nalidixic acid 100.0 99.2 
Streptomycin - 100.0 
Sulphonamides 97.6 - 
Temocillin 99.2 - 
Tetracycline 100.0 98.8 
Tigecycline 100.0 - 
Trimethoprim 99.2 - 
 
3.1, the results related to the 
strain/antimicrobial combination were 
disregarded, consequently also the results in 
relation to categorisation as ESBL-phenotype or 
AmpC/ESBL phenotype were disregarded.  
In total, the categorisation as ESBL-, AmpC- or 
carbapenemase-producer for the eight  strains 
was correct in 218 out of 224 reported results. 
Of the results that were considered incorrect 
(N=6), three could be attributed to laboratory 
#64. The MIC results obtained by laboratory 
#64 for S-13.4 and S-13.5, however, do not 
indicate any reason for the incorrect ESBL-, 
AmpC- or carba-categorisation. The laboratory 
reported that the task was overlooked when the 
EQAS was performed, and consequently the 
results were submitted in spite of missing 
background information. 
3.3.2 Campylobacter trial 
For the Campylobacter strains, 99.5% of AST 
results were correct. Table 1 presents that the 
variation between the strains in the obtained 
correct results ranged from 98.9 to 100% and 
Table 2 illustrates that the percentage of correct 
AST per antimicrobial were all above 98.8%. 
The participants were requested to identify the 
Campylobacter species as C. jejuni or C. coli. 
All 31 laboratories delivered in total 248 results 
of which all were in accordance with the 
expected. 
3.4 Deviations by laboratory 
Figure 3 and 4 illustrate the percentage of 
deviations for each participating laboratory. The 
laboratories are ranked according to their 
performance determined by the percentage of 
deviating results in the antimicrobial 
susceptibility tests. 
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Table 3: Overview of ESBL-, AmpC- and carbapenemase-producing Salmonella test strains and proportion of 
laboratories that obtained the expected result; number and percentages of laboratories which correctly detected and 
confirmed the ESBL-, AmpC- and carbapenemase-producing Salmonella strains.  
Fields shaded in grey with numbers in italics indicate an unexpected result.  
Grey text indicates results that is disregarded for further analysis. 
Strain code S -13.1 S-13.4  S-13.6 S-13.7* S-13.8 
ESBL/AmpC/carbapenemase-
encoding genes harboured in 
the test strain 
blaCTX-M-8 
 blaCTX-M-9 
blaTEM-1B 
blaOXA-48 
blaSHV-12 
blaCTX-M-15 
blaCTX-M-3 
blaTEM-1B 
ESBL-, AmpC- and carbapenemase-
producing strain – expected results ESBL ESBL carbapenemase ESBL* ESBL 
O
bt
ai
ne
d 
re
su
lts
 Confirmed ESBL-producer 32/32 (100%) 31/32 (97%) - 23/32 (72%) 32/32 (100%) 
Confirmed ESBL + AmpC-
producer - - - 9/32 (28%) - 
Confirmed AmpC-producer - - - - - 
Confirmed carbapenemase-
producer - - 29/32 (91%) - - 
Confirmed other phenotype - - 1/32 (3%) - - 
Not ESBL-, AmpC-  
or carbapenemase-producing - 1/32 (3%) 2/32 (6%) - - 
* Results from strain S-13.7 were disregarded for further analysis in this report due to the fact that for a number of laboratories (n=9) the cefoxitin 
MIC value indicated an ESBL + AmpC producer even if the MIC-value was within the method acceptance limit (± one one-fold dilution step). 
 
Figure 3: Individual participants’ deviations in percent of their total number of Salmonella AST’s.  
 
Figure 4: Individual participants’ deviations in percent of their total number of Campylobacter AST’s. 
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Table 4 Obtained values for AST of E. coli ATCC 25922. 
AMP; ampicillin, FEP; cefepime FOT; cefotaxime, FOX; 
cefoxitin, TAZ; ceftazidime, CHL; chloramphenicol, CIP; 
ciprofloxacin, COL; colistin, ERT: ertapenem, GEN; 
gentamicin, IMI; imipenem, MER; meropenem, NAL; 
nalidixic acid, SMX; sulphonamides, TET; tetracycline, 
TGC; tigecycline, TMP; trimethoprim. 
MIC determination E. coli ATCC 25922 
Antimicrobial 
Proportion 
outside QC 
range 
Obtained values in MIC 
steps (min/max) 
Below lower 
QC limit 
Above 
upper QC 
limit 
Panel 1, AMP 0/32 (0%) - - 
Panel 1, FOT 1/31 (3%) - 1 step 
Panel 1, TAZ 0/32 (0%) - - 
Panel 1, CHL 0/32 (0%) - - 
Panel 1, CIP 0/32 (0%) - - 
Panel 1, COL 0/32 (0%) - - 
Panel 1, GEN 1/32 (3%) 2 steps - 
Panel 1, MER 0/32 (0%) - - 
Panel 1, NAL 0/32 (0%) - - 
Panel 1, SMX 0/31 (0%) - - 
Panel 1, TET 0/32 (0%) - - 
Panel 1, TGC 1/32 (3%) - 1 step 
Panel 1, TMP 2/32 (6%) 1 step - 
Panel 2, FEP 0/28 (0%) - - 
Panel 2, FOT 0/28 (0%) - - 
Panel 2, FOX 0/29 (0%) - - 
Panel 2, TAZ 0/29 (0%) - - 
Panel 2, ERT 0/29 (0%) - - 
Panel 2, IMI 0/29 (0%) - - 
Panel 2, MER 0/29 (0%) - - 
Table 5 Obtained values for AST of C. jejuni ATCC 33560. 
CIP; ciprofloxacin, ERY; erythromycin, GEN; gentamicin, 
NAL; nalidixic acid, TET; tetracycline. 
MIC determination C. jejuni ATCC 33560 
Antimicrobial 
Proportion 
outside QC 
range 
Obtained values in MIC 
steps (min/max) 
Below lower 
QC limit 
Above upper 
QC limit 
CIP 0/30 (0%) - - 
ERY 0/29 (0%) - - 
GEN 3/30 (10%) 1 step - 
NAL 0/30 (0%) - - 
TET 1/30 (3%) - 1 step 
 
 
3.4.1 Salmonella trial  
All 32 participating laboratories obtained a 
result within the acceptance limit (< 5% 
deviations) for the Salmonella strains. The 
maximum percentage of deviations was at 
4.9%, presenting acceptable result across the 
EURL-AR network. 
3.4.2 Campylobacter trial 
In the Campylobacter trial, most laboratories 
performed very well. Applying the 5% 
acceptance threshold, 30 of 31 participating 
laboratories performed acceptably, with 26 
laboratories having no deviations (Figure 4). 
One laboratory presented a deviation level at 
8.3%, i.e. above the 5% acceptance level (#14).  
3.5 Deviations by reference strains  
In the following section, deviations are defined 
as results of antimicrobial susceptibility tests on 
the reference strain that are outside the quality 
control (QC) acceptance intervals (Appendix 5).  
Obtained values from the participants’ testing of 
the QC strains are listed in Appendix 6a and 6b, 
and in Tables 4 and 5. For the Salmonella and 
Campylobacter trial, 32 and 28 laboratories, 
respectively, uploaded data from testing of the 
relevant QC strain. 
Appendix 6a presents the results for the 
reference strain E. coli ATCC 25922. Four 
laboratories produced in total five values 
outside the acceptable range. Table 4 illustrates 
the obtained results which are fully presented in 
Appendix 6a.  
Table 5 presents the proportion of the 
laboratories submitting AST-results for the C. 
jejuni reference strain ATCC 33560 with results 
below or above the acceptable range. Four 
deviations were observed from four different 
laboratories. 
3.6 Genotypic characterisation 
For the optional genotypic characterisation of 
the ESBL-, AmpC-, and carbapenemase-
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producing Salmonella test strains, 11 
laboratories participated. In Appendix 9, 
information is presented on detected genes, 
primers used, and references for the method 
used. Five laboratories reported results based 
on whole genome sequencing of the ESBL-, 
AmpC- and carbapenemase-producing 
Salmonella whereas five laboratories indicated 
the use of various types of PCR to identify the 
relevant genes. The remaining laboratory 
applied both WGS and PCR for the detection of 
the ESBL-, AmpC- and carbapenemase-
encoding genes. Table 6 indicates the obtained 
results, both on family and variant level. 
Moreover, Figure 5 indicates that two 
discordant results related to one gene and one 
variant were submitted by two different 
laboratories. These were related to the blaDHA 
gene and a variant of the blaCTX-M gene.  
 
Figure 5: Deviations as a percentage of the total number 
of results (i.e. detected genes) reported by each 
participant.  
 
 
Table 6: Results from the participation of eleven laboratories in the optional genotypic characterisation component of the 
EQAS.  
Strain code Expected gene Proportion of correct results (family level) 
Proportion of correct 
results (variant level) 
Unexpected 
genes/variants identified 
S-13.1 blaCTX-M-8 10/10 (100%) 8/8 (100%) blaDHA (n=1) 
S-13.4 
blaCTX-M-9 11/11 (100%) 8/8 (100%)  
blaTEM-1/1B 9/9 (100%) 7/7 (100%) 
S-13.6 blaOXA-48 11/11 (100%) 10/10 (100%)  
S-13.7 
blaSHV-12 11/11 (100%) 8/8 (100%)  
blaCTX-M-15 11/11 (100%) 9/9 (100%) 
S-13.8 
blaCTX-M-3 11/11 (100%) 7/8 (88%) blaCTX-M-15 (n=1) blaTEM-1/1B 9/9 (100%) 8/8 (100%) 
 
4. Discussion 
The number of participating laboratories was at 
comparable levels in 2018 as in 2017; for the 
Salmonella EQAS, 31 and 32 participated in 
2017 and 2018, respectively, and for 
Campylobacter EQAS, 30 and 31 participated 
in 2017 and 2018. This allows for a fair 
comparison between the two EQAS periods for 
both organisms.  
As also specified in the EU regulation 
2013/652/EU, all participants in the present 
EQAS performed AST by broth microdilution.  
This 2018 proficiency test was the fifth 
possibility of testing Salmonella and 
Campylobacter strains with the panels designed 
to follow the requirements of Decision 
2013/652/EU.  
4.1 Salmonella trial  
Overall, the percentage of correct antimicrobial 
susceptibility test results of Salmonella was 
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99.0%. All (n=32) participants obtained 
satisfactory results according to the level of 
acceptance (<5% deviation) (Figure 3). When 
comparing between the antimicrobials, the 
testing of cefoxitin appeared to cause most 
problems (94.5% correct results).  
As indicated in Figure 2, the overall quality of 
the results in the 2018-EQAS would appear to 
be at the same high level as in 2017, also, 
when comparing results obtained from testing 
the internal control strain a steady and very 
good quality of Salmonella AST results was 
observed.  
Based on these results, follow-up has not been 
necessary and none of the laboratories was 
defined as outlier. 
For the E. coli reference strain, the obtained 
results were in general in agreement with the 
CLSI recommendations.  
Follow up on previous EQAS results was not 
relevant as no laboratories had deviation levels 
for the AST results above the acceptance limit 
in EQAS 2017.  
ESBL/AmpC/carbapenemase-producing 
Salmonella test strains 
The phenotypic detection of ESBL-, AmpC- and 
carbapenemase-producing microorganisms 
remains to be important and is a mandatory 
part of this EQAS.  
Of the five Salmonella test strains relevant for 
this component of the EQAS (S-13.1, S-13.4, S-
13.6, S-13.7, and S-13.8), one was a  
carbapenemase producer (S-13.6) and four 
were ESBL-producers. One of the strains (S-
13.7) was problematic due to an MIC for 
cefoxitin at the breakpoint causing the strain to 
be categorised as an AmpC+ESBL-producer by 
9 of 32 laboratories whereas the expected 
category was ‘ESBL-producer’. Therefore, this 
strain was therefore disregarded for the 
evaluation.  
The testing and interpretation of results for the 
ESBL- and carbapenemase-producing strains 
appeared not to cause difficulties. One 
laboratory (#64), however, obtained three of the 
total number of six deviations though these 
incorrect categorisations could not be explained 
by the submitted MIC results. Follow-up has 
been done directly with the laboratory to identify 
what might be done to improve the 
interpretation performance.  
Even if no acceptance limit has been defined 
for this component of the EQAS, the overall 
result appears satisfactory.  
4.2 Campylobacter trial  
For the Campylobacter component of this 
year’s EQAS, 31 laboratories submitted results 
leading to an overall percentage of correct AST 
results at 99.5%. The performance varied from 
no deviations to up to 8.3% deviations, with 30 
laboratories performing satisfactorily according 
to the established acceptance range.  
It appears that the level of deviations for the 
overall AST results is similar to the EQAS 2017, 
also in relation to the results obtained from 
testing the internal control strain (Figure 2).  
One laboratory (#14) obtained deviation levels 
above 5%. For this laboratory, the four obtained 
deviations that caused the 8.3% deviation level 
were related to two strains (C-13.1 and C-13.6) 
and to the testing of nalidixic acid and 
tetracycline and indicate that a switch of strains 
may have happened. 
All participating laboratories except one (#29) 
uploaded data for tests performed on the C. 
jejuni reference strain and the proportion of 
results within the acceptable range was 97.3%.  
All four values outside the QC intervals were 
one step below or above the QC-limits. It is 
suggested that these values are monitored over 
time to ensure that the tests render a reliable 
result for the particular antimicrobial. 
In 2017, one laboratory (#40) obtained AST 
results outside the acceptance limit (at 10.4%). 
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The EURL-AR followed-up directly with this 
laboratory and conveyed suggestions for 
improvements for performing AST’s. This year, 
laboratory #40 obtained no deviations when 
performing Campylobacter AST. 
4.3 Genotypic characterisation 
One of the unexpected results, blaDHA reported 
by laboratory #32, was reported due to a 
transcription error (an error in the drop-down 
tab of EQAS data entry). 
Genotypic characterisation of microorganisms 
has been applied in a number of laboratories 
and work is ongoing to improve laboratory 
detection of antimicrobial resistance genes, 
including identification of ESBL-, AmpC-, and 
carbapenemase-producing Enterobacteriaceae. 
The optional genotypic characterisation is a 
supplementary component of this EQAS and 
should therefore be seen as an important 
possibility for the NRL-AR’s to introduce or 
improve these methods in the laboratory. This 
year, eleven laboratories participated in the 
optional EQAS component and even though no 
acceptance limit has been defined, the 98.7% 
correct results (N=150) appears to be a very 
satisfactory result.  
5. Conclusions 
The goal of the EURL-AR EQAS is to have all 
participating NRLs performing antimicrobial 
susceptibility testing of Salmonella and 
Campylobacter with a deviation level below 5%. 
This year, this goal was reached for both 
Salmonella and Campylobacter.  
Compared to the EQAS 2017, the performance 
of the NRL’s in 2018 appears to be at the same 
high level for Salmonella AST’s (99.0% in 2018 
and 99.3% in 2017) as well as for 
Campylobacter (99.5% in 2018 and 99.3% in 
2017)  (Figure 2). 
The test covering the identification of the 
phenotype of Salmonella test strains producing 
beta-lactamases of the ESBL-, AmpC, and 
carbapenemase type rendered six deviations 
(97.3% correct categorisations). This is a 
priority area within the EURL-AR activities, and 
the focus on identifying ESBL-, AmpC-, and 
carbapenemase-producing organisms is 
encouraged. 
Eleven NRLs participated in the EQAS 
component consisting of genotypic testing of 
ESBL-, AmpC- and carbapenemase-producing 
Enterobacteriaceae presenting satisfactory 
results.  
Finally, the EURL-AR is open to suggestions to 
improve future EQAS trials and invites the 
entire network to contribute with ideas for 
training courses and specific focus areas to 
expand the network’s knowledge in 
antimicrobial resistance. 
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EU Reference Laboratory for Antimicrobial Resistance 
External Quality Assurance System (EQAS) 2018 
G00-06-001/23.06.2017 
EQAS 2018 FOR SALMONELLA, CAMPYLOBACTER AND OPTIONAL GENOTYPIC 
CHARACTERISATION  
The EURL-AR announces the launch of another EQAS, thus providing the opportunity for 
proficiency testing which is considered an essential tool for the generation of reliable laboratory 
results of consistently good quality. 
This EQAS consists of antimicrobial susceptibility testing of eight Salmonella isolates and eight 
Campylobacter isolates. Additionally, quality control (QC) strains E. coli ATCC 25922 (CCM 
3954) and C. jejuni ATCC 33560 (CCM 6214) will be distributed to new participants.  
It is the recipients’ responsibility to comply with national legislation, rules and regulation regarding 
the correct use and handling of the provided strains and to possess the proper equipment and 
protocols to handle these strains. 
This EQAS is specifically for NRL’s on antimicrobial resistance (NRL-AR). Laboratories 
designated to be NRL-AR do not need to sign up to participate but are automatically regarded as 
participants. You may contact the EQAS-Coordinator if you wish to inform of changes in relation to 
your level of participation in compared to previous years. The EURL-AR will be able to cover the 
expenses for one parcel, only, per EU Member State. Therefore, countries with more than one 
laboratory registered on the EURL-AR contact-list will be contacted directly to confirm which 
laboratory will be included for participation free of charge.  
The invitation to participate in the proficiency test is extended to additional participants besides 
official NRLs and to participants from laboratories which are involved in the network but are not 
designated NRLs (cost for participation will be 100 EUR). 
TO AVOID DELAY IN SHIPPING THE ISOLATES TO YOUR LABORATORY 
The content of the parcel is “UN3373, Biological Substance Category B”: Eight Salmonella strains, 
eight Campylobacter and for new participants also the QC strains mentioned above. Please provide 
the EQAS coordinator with documents or other information that can simplify customs procedures 
(e.g. specific text that should be written on the proforma invoice). To avoid delays, we kindly ask 
you to send this information already at this stage.  
TIMELINE FOR RESULTS TO BE RETURNED TO THE NATIONAL FOOD INSTITUTE 
Shipment of isolates and protocol: The isolates will be shipped in October 2018. The protocol for 
this proficiency test will be available for download from the website (www.eurl-ar.eu).  
Submission of results: Results must be submitted to the National Food Institute no later than 
December 7th 2018 via the password-protected website.  
Upon reaching the deadline, each participating laboratory is kindly asked to enter the password-
protected website once again to download an automatically generated evaluation report. 
EQAS report: A report summarising and comparing results from all participants will be issued. In 
the report, laboratories will be presented coded, which ensures full anonymity. The EURL-AR and 
the EU Commission, only, will have access to un-coded results. The report will be publicly 
available. 
Appendix 1, page 1 of 2
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EU Reference Laboratory for Antimicrobial Resistance 
External Quality Assurance System (EQAS) 2018 
Next EQAS: The next EURL-AR EQAS that we will have is on antimicrobial susceptibility testing 
of E. coli, staphylococci and enterococci which will be carried out in June 2019.  
Please contact me if you have comments or questions regarding the EQAS. 
Sincerely, 
Susanne Karlsmose Pedersen 
EURL-AR EQAS-Coordinator 
Appendix 1, page 2 of 2
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Participant list
Salmonella Campylobacter Genotypic characterisation Institute  Country
X X X Austrian Agency for Health and Food Safety Austria
X X - Sciensano Belgium
X X - National Diagnostic and Research Veterinary Institute Bulgaria
X X - Croatian Veterinary Institut Croatia
X X - Veterinary Services Cyprus
X X X State Veterinary Institute Praha Czech Republic
X* X* X DTU National Food Institute Denmark
X X - Danish Veterinary and Food Administration, DVFA Denmark
X X - Estonian Veterinary and Food Laboratory Estonia
X X - Finnish Food Authority Finland
X - - Agence nationale de sécurité sanitaire ANSES - Fougères LERMVD France
- X - Agence nationale de sécurité sanitaire ANSES - Ploufragan - LERAP France
X X X Federal Institute for Risk Assessment Germany
X X - Veterinary Laboratory of Chalkis Greece
X X - Central Agricultural Office Veterinary Diagnostic Directorate Hungary
X X - University of Iceland Iceland
X X X Central Veterinary Research Laboratory Ireland
X X X Istituto Zooprofilattico Sperimentale delle Regioni Lazio e Toscana Italy
X X X Institute of Food Safety, Animal Health and Enviroment "BIOR" Latvia
X X - National Food and Veterinary Risk Assessment Institute Lithuania
X X - Laboratoire National de Santé Luxembourg
X X - Public Health Laboratory Malta
X X X Central Veterinary Institute of Wageningen UR Netherlands
X* X* - Food and Consumer Product Safety Authority (VWA) Netherlands
X X X Veterinærinstituttet Norway
X X - National Veterinary Research Institute Poland
X X - Laboratorio National de Investigacáo Veterinaria Portugal
X X - Institute for Hygiene and Veterinary Public Health Romania
X* X* X* Institute for Diagnosis and Animal Health Romania
X X - State Veterinary and Food Institute  (SVFI) Slovakia 
X X - National Veterinary Institute Slovenia
X X X Laboratorio Central de Sanidad, Animal de Algete Spain
X* - - Centro Nacional de Alimentación (AECOSAN) Spain
X* X* - VISAVET Health Surveillance Center, Complutense University Spain
X X X National Veterinary Institute, SVA Sweden
X X - Vetsuisse Faculty Bern, Institute of Veterinary Bacteriology Switzerland
X - - Faculty of Veterinary Medicine - Skopje The former Yugoslav Republic of Macedonia
X* X* - Agri-Food and Biosciences Institute (AFBI) United Kingdom
X* - - Public Health England United Kingdom
X X - Animal Plant Health Agency United Kingdom
Designated NRL-AR by the compentent authority of the member state
Non-NRL-AR enrolled by the EURL-AR
Not a Member State of the EU
* Submitted results were not included in the current report (allows for one dataset per country, only)
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Reference values (MIC-value and interpretation) - Salmonella 
Ampicillin Azithromycin Cefepime Cefotaxime Cefotaxime/clav F:F/C Cefoxitin Ceftazidime Ceftazidime/clav T:T/C Chloramphenicol Ciprofloxacin Colistin Ertapenem
AMP AZI FEP FOT F/C ratio FOX TAZ T/C ratio CHL CIP COL
EURL 2018 S-13.1 >64 RESIST 8 SUSC 32 NA 64 RESIST 0.12 >=8 8 SUSC 4 RESIST 0.5 >=8 <=8 SUSC 0.03 SUSC <=1 SUSC <=0.015 SUSC
EURL 2018 S-13.2 >64 RESIST >64 RESIST <=0.25 SUSC <=0.5 SUSC <=8 SUSC <=0.015 SUSC <=1 SUSC
EURL 2018 S-13.3 2 SUSC 4 SUSC <=0.25 SUSC <=0.5 SUSC <=8 SUSC <=0.015 SUSC <=1 SUSC
EURL 2018 S-13.4 >64 RESIST 8 SUSC 2 NA 16 RESIST 0.12 >=8 4 SUSC 1 SUSC 0.25 <8 <=8 SUSC 0.5 RESIST <=1 SUSC <=0.015 SUSC
EURL 2018 S-13.5 <=1 SUSC 4 SUSC <=0.25 SUSC <=0.5 SUSC <=8 SUSC 0.03 SUSC 4 RESIST
EURL 2018 S-13.6 >64 RESIST 32 RESIST 0.12 NA 0.5 SUSC 0.5 <8 8 SUSC 0.5 SUSC 0.5 <8 <=8 SUSC 8 RESIST <=1 SUSC 0.5 RESIST
EURL 2018 S-13.7 >64 RESIST 16 SUSC >32 NA >64 RESIST 0.5 >=8 16 RESIST >128 RESIST 2 >=8 >128 RESIST 0.03 SUSC <=1 SUSC 0.06 SUSC
EURL 2018 S-13.8 >64 RESIST >64 RESIST >32 NA >64 RESIST 0.12 >=8 4 SUSC 16 RESIST 0.5 >=8 <=8 SUSC 0.03 SUSC <=1 SUSC <=0.015 SUSC
Gentamicin IMIPENEM MEROPENEM Nalidixic acid Sulfamethoxazole TEMOCILLIN Tetracycline TIGECYCLINE Trimethoprim
GEN IMI MER NAL SMX TRM TETRA TGC TMP ESBL-category Relevant genes
EURL 2018 S-13.1 <=0.5 SUSC 0.25 SUSC <=0.03 SUSC <=4 SUSC >1024 RESIST 8 SUSC >64 RESIST 0.5 SUSC <=0.25 SUSC
EURL 2018 S-13.2 <=0.5 SUSC <=0.03 SUSC <=4 SUSC 32 SUSC <=2 SUSC <=0.25 SUSC <=0.25 SUSC
EURL 2018 S-13.3 <=0.5 SUSC <=0.03 SUSC <=4 SUSC 32 SUSC <=2 SUSC <=0.25 SUSC <=0.25 SUSC
EURL 2018 S-13.4 1 SUSC 0.25 SUSC <=0.03 SUSC >128 RESIST 32 SUSC 8 SUSC 64 RESIST <=0.25 SUSC <=0.25 SUSC
EURL 2018 S-13.5 <=0.5 SUSC <=0.03 SUSC <=4 SUSC >1024 RESIST <=2 SUSC <=0.25 SUSC >32 RESIST
EURL 2018 S-13.6 <=0.5 SUSC 2 RESIST 0.5 RESIST >128 RESIST <=8 SUSC >128 RESIST <=2 SUSC 0.5 SUSC <=0.25 SUSC
EURL 2018 S-13.7 >32 RESIST 0.5 SUSC 0.06 SUSC <=4 SUSC >1024 RESIST 64 RESIST >64 RESIST 0.5 SUSC >32 RESIST
EURL 2018 S-13.8 >32 RESIST 0.25 SUSC <=0.03 SUSC <=4 SUSC >1024 RESIST 8 SUSC <=2 SUSC 0.5 SUSC >32 RESIST
Resistant
SHV-12
CTX-M-15
CTX-M-3
TEM-1/1B
ingen
CTX-M-9
TEM-1/1B
CTX-M-8
ingen
ingen
OXA-48
none
none
ESBL-phenotype
ESBL-phenotype
ESBL-phenotype
carbapenemase-phenotype
none
ESBL-phenotype
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Appendix 3b, page 1 of 1Reference values (MIC-value and interpretation) - Campylobacter 
Ciprofloxacin Erythromycin Gentamicin Nalidixic acid Streptomycin Tetracycline
Species Code CIP ERY GEN NAL STR TET
C. jejuni EURL 2018 C-13.1 4 RESIST <=1 SUSC 0.25 SUSC 64 RESIST <=0.25 SUSC 32 RESIST
C. coli EURL 2018 C-13.2 0.25 SUSC >128 RESIST 1 SUSC 8 SUSC 2 SUSC 2 SUSC
C. coli EURL 2018 C-13.3 >16 RESIST 4 SUSC 1 SUSC >64 RESIST >16 RESIST >64 RESIST
C. jejuni EURL 2018 C-13.4 16 RESIST >128 RESIST >16 RESIST 64 RESIST >16 RESIST 64 RESIST
C. jejuni EURL 2018 C-13.5 <=0.12 SUSC <=1 SUSC 0.5 SUSC 4 SUSC 1 SUSC <=0.5 SUSC
C. jejuni EURL 2018 C-13.6 8 RESIST <=1 SUSC 0.25 SUSC <=1 SUSC 1 SUSC <=0.5 SUSC
C. coli EURL 2018 C-13.7 <=0.12 SUSC >128 RESIST 1 SUSC 8 SUSC >16 RESIST <=0.5 SUSC
C. jejuni EURL 2018 C-13.8 8 RESIST 1 SUSC 0.5 SUSC >64 RESIST >16 RESIST <=0.5 SUSC
Resistant
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Ph: +45 3588 6601, e-mail: suska@food.dtu.dk 
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EURL-AR External Quality Assurance System 2018   
- Salmonella, Campylobacter and optional genotypic characterisation  
 
Id: «Lab_no_» 
«Name» 
«Institute__»  
«Country» 
Kgs. Lyngby, October 2018 
 
Dear «Name», 
 
Please find enclosed the bacterial strains for the EURL-AR EQAS 2018: eight Salmonella spp. 
and eight Campylobacter spp. Upon arrival to your laboratory, the strains should be stored in a 
dark place at 4°C for stabs, and in a dark and cool place for freeze-dried strains. Charcoal swabs 
must be subcultured upon arrival.  
 
On the EURL-AR-website (www.eurl-ar.eu) the following documents relevant for this EURL-AR 
EQAS are available: 
- Protocol for antimicrobial susceptibility testing of Salmonella and Campylobacter and test 
forms for reporting results  
- Instructions for Opening and Reviving Lyophilised Cultures 
- Subculture and Maintenance of Quality Control Strains 
 
We ask you to test these Salmonella and Campylobacter strains for antimicrobial susceptibility. 
Detailed description of the procedures to follow for antimicrobial susceptibility testing, for 
optional genotypic characterization and for entering your results into the interactive web database 
can be found in the protocol. For accessing the database, you need this username and password. 
 
 
Your username: «Username» 
 
Your password: «Password» 
 
Please keep this document 
  Your username and password will not appear in other documents 
 
 
Results should be submitted to the database no later than 7th December 2018. 
 
Please acknowledge receipt of this parcel immediately upon arrival (to suska@food.dtu.dk).  
Do not hesitate to contact me for further information. 
 
Yours sincerely, 
 
Susanne Karlsmose Pedersen 
EURL-AR EQAS-Coordinator 
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PROTOCOL 
For antimicrobial susceptibility testing of Salmonella, Campylobacter and optional 
genotypic characterisation of AmpC-, ESBL- and carbapenemase-producing test strains 
1 INTRODUCTION  ................................................................................................................... 1 
2 OBJECTIVES  .......................................................................................................................... 2 
3 OUTLINE OF THE SALM/CAMP EQAS 2018  .................................................................. 2 
3.1    Shipping, receipt and storage of strains  .............................................................. 2 
3.2    QC reference strains  ............................................................................................. 2 
3.3    Antimicrobial susceptibility testing ..................................................................... 3 
3.4    Optional genotypic characterisation ..................................................................... 5 
4 REPORTING OF RESULTS AND EVALUATION  ........................................................... 6 
5 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE  ............................. 6 
APPENDIX  ........................................................................................................................................ 8 
1 INTRODUCTION 
The organisation and implementation of an External Quality Assurance System (EQAS) on 
antimicrobial susceptibility testing (AST) of Salmonella and Campylobacter is among the tasks of 
the EU Reference Laboratory for Antimicrobial Resistance (EURL-AR). The 
Salmonella/Campylobacter EQAS 2018 will include AST of eight Salmonella and Campylobacter 
strains and AST of reference strains E. coli ATCC 25922 (CCM 3954) and C. jejuni ATCC 33560 
(CCM 6214).  
The reference strains are included in the parcel only for new participants of the EQAS who did not 
receive them previously. The reference strains are original CERTIFIED cultures provided free of 
charge, and should be used for future internal quality control for antimicrobial susceptibility testing 
in your laboratory. The reference strains will not be included in the years to come. Therefore, please 
Appendix 4b, page 1 of 8
The 25th EURL-AR Proficiency Test Salmonella, Campylobacter and genotypic characterisation (2018), final version, 1 ed.
EU Reference Laboratory for Antimicrobial Resistance  
External Quality Assurance System (EQAS) 2018 
 
 
 
Page 2 of 8 
G00-06-001/23.06.2017 
take proper care of these strains. Handle and maintain them as suggested in the manual ‘Subculture 
and Maintenance of QC Strains’ available on the EURL-AR website (see www.eurl-ar.eu).  
Various aspects of the proficiency test scheme may from time to time be subcontracted. When 
subcontracting occurs it is placed with a competent subcontractor and the National Food Institute is 
responsible to the scheme participants for the subcontractor’s work. 
2 OBJECTIVES 
This EQAS aims to support laboratories to assess and, if necessary, to improve the quality of results 
obtained by AST of pathogens of food- and animal-origin, with special regard to Salmonella and 
Campylobacter. Further objectives are to evaluate and improve the comparability of surveillance 
data on antimicrobial susceptibility of Salmonella and Campylobacter reported to EFSA by 
different laboratories. 
3 OUTLINE OF THE SALM/CAMP EQAS 2018 
3.1    Shipping, receipt and storage of strains 
In October 2018, the National Reference Laboratories for Antimicrobial Resistance (NRL-AR) will 
receive a parcel containing eight Salmonella and Campylobacter strains from the National Food 
Institute. This parcel will also contain reference strains, but only for participants who did not 
receive them previously.  
All strains belong to UN3373, Biological substance, category B. Extended spectrum beta-lactamase 
(ESBL)-producing strains as well as carbapenemase producing strains are included in the selected 
material and are part of the optional EQAS-item, consisting of characterization of genes conferring 
ESBL- or carbapenemase production. It is the recipients’ responsibility to comply with national 
legislation, rules and regulation regarding the correct use and handling of the provided strains and to 
possess the proper equipment and protocols to handle these strains. 
The reference strains are shipped lyophilised, the Campylobacter test strains are shipped as a 
charcoal swabs and the Salmonella test strains are stab cultures. On arrival, the stab cultures and the 
charcoal swabs must be subcultured, and all cultures should be adequately stored until testing. A 
suggested procedure for reconstitution of the lyophilised reference strains is presented below. 
3.2 QC reference strains  
For a suggested procedure for reconstitution of the lyophilised, please refer to the document 
‘Instructions for opening and reviving lyophilised cultures’ on the EURL-AR-website (see 
www.eurl-ar.eu). 
Note that, for the testing of the E. coli ATCC25922 reference strain, the two compounds, 
sulfamethoxazole and sulfisoxazole, are regarded as comparable, i.e. the obtained MIC-value from 
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the testing of sulfamethoxazole will be evaluated against the acceptance range listed in CLSI M100 
for sulfisoxazole.  
 
3.3 Antimicrobial susceptibility testing 
The strains should be tested for susceptibility to the antimicrobials listed in Tables 1, 2 and 3, using 
the method implemented in your laboratory for performing monitoring for EFSA and applying the 
interpretative criteria listed below. 
Participants should perform minimum inhibitory concentration (MIC) determination using the 
methods stated in the EC regulation EC 652/2013. For interpretation of the results, use the cut-off 
values listed in Tables 1, 2 and 3. Except where indicated, these represent the current 
epidemiological cut-off values developed by EUCAST (www.eucast.org), and allow categorisation 
of bacterial isolates into two categories; resistant or susceptible. A categorisation as intermediate is 
not accepted.  
As the current regulation and recommendations focus on MIC testing only, results obtained by disk 
diffusion cannot be submitted. 
3.3.1 Salmonella. 
The interpretative criteria that should be applied for categorizing the Salmonella test strain as 
resistant or susceptible are those listed in Tables 1 and 2.  
Table 1: Antimicrobials recommended for AST of Salmonella spp. and interpretative criteria according to 
table 1 in EC regulation 652/2013 
Antimicrobial MIC (µg/mL) (R>) 
Ampicillin (AMP) 8 
Azithromycin (AZI) 16* 
Cefotaxime (FOT) 0.5 
Ceftazidime (TAZ) 2 
Chloramphenicol (CHL) 16 
Ciprofloxacin (CIP) 0.064 
Colistin (COL) 2 
Gentamicin (GEN) 2 
Meropenem (MERO) 0.125 
Nalidixic acid (NAL) 16 
Sulfonamides (SMX) 256** 
Tetracycline (TET) 8 
Tigecycline (TGC) 1*** 
Trimethoprim (TMP) 2 
* Tentative value 
** CLSI M100 Table 2A 
*** Data from EUCAST is available for S. Enteritidis, S. Typhimurium, S. Typhi and S. Paratyphi (for the 
purpose of this proficiency test, the ECOFF at 1 is applied) 
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Table 2: Antimicrobials recommended for additional AST of Salmonella spp. resistant to cefotaxime, 
ceftazidime or meropenem and interpretative criteria according to table 4 in EC regulation 652/2013 
Antimicrobial MIC (µg/mL) (R>) 
Cefepime, FEP Not available* 
Cefotaxime, FOT 0.5 
Cefotaxime + clavulanic acid (F/C) Not applicable 
Cefoxitin, FOX 8 
Ceftazidime, TAZ 2 
Ceftazidime+ clavulanic acid (T/C) Not applicable 
Ertapenem, ETP 0.06 
Imipenem, IMI 1 
Meropenem, MERO 0.125 
Temocillin, TRM 32** 
* Participants are requested to upload the MIC value obtained without selecting an interpretation 
** Tentative value 
 
Plasmid-mediated quinolone resistance  
When performing antimicrobial susceptibility testing of the Salmonella test strains, the 
interpretative criteria listed in Table 1 for results obtained by MIC-determination should allow 
detection of plasmid-mediated quinolone resistant test strains.  
Beta-lactam- and carbapenem resistance  
Confirmatory tests for ESBL production are mandatory on all strains resistant to cefotaxime 
(FOT), ceftazidime (TAZ) and/or meropenem and should be performed by testing the second panel 
of antimicrobials (Table 2 in this document corresponding to Table 4 in Commission Implementing 
Decision 2013/652/EU). 
Confirmatory test for AmpC-, ESBL- and carbapenemase production requires use of both 
cefotaxime (FOT) and ceftazidime (TAZ) alone and in combination with a β-lactamase inhibitor 
(clavulanic acid). Synergy is defined either as i) a ≥ 3 twofold concentration decrease in an MIC for 
either antimicrobial agent tested in combination with clavulanic acid vs. the MIC of the agent when 
tested alone (MIC FOT:FOT/Cl or TAZ:TAZ/Cl ratio ≥ 8) (CLSI M100 Table 3A, Tests for 
ESBLs). The presence of synergy indicates ESBL production.  
Confirmatory test for carbapenemase production requires the testing of meropenem (MERO).  
Detection of AmpC-type beta-lactamases can be performed by testing the bacterium for 
susceptibility to cefoxitin (FOX). Resistance to FOX could indicate the presence of an AmpC-type 
beta-lactamase. 
The classification of the phenotypic results should be based on the most recent EFSA 
recommendations (available in The European Union summary report on antimicrobial resistance in 
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zoonotic and indicator bacteria from humans, animals and food in 2015, EFSA Journal 
2017;15(2):4694,212 pp. (page 43), and in the appendix to this protocol). It is important to notice 
that two cut-off values apply for cefotaxime and ceftazidime: the EUCAST cut-off values 
(ECOFFs: FOT>0.5 and TAZ>2), which are those used to define R/S, and the screening cut-off 
values (FOT>1 and TAZ>1), which are those applied to categorise bacterial phenotypes as ESBL, 
AmpC, carbapenemase, etc. based on panel 2 results (see Appendix).  
 
3.3.2 Campylobacter   
The obtained values of the C. jejuni QC reference strain will be evaluated according to the values 
listed in the CLSI document VET06, 1st ed., i.e. based on incubation at 36-37ºC for 48 hours or 
42ºC for 24 hours.  
Table 3: Antimicrobials recommended for AST of Campylobacter jejuni and C. coli and 
interpretative criteria according to table 1 in EC regulation 652/2013 
Antimicrobial C. jejuni C. coli 
MIC (µg/mL) (R>) MIC (µg/mL) (R>) 
Ciprofloxacin (CIP) 0.5 0.5 
Erythromycin (ERY) 4 8 
Gentamicin (GEN) 2 2 
Nalidixic acid (NAL) 16 16 
Streptomycin (STR) 4 4 
Tetracycline (TET) 1 2 
 
 
Identification of Campylobacter species 
Species identification of the Campylobacter test strains must be performed by the NRLs using in-
house methods or adopting the protocol available on the EURL-AR website under: http://eurl-
ar.eu/233-protocols.htm. 
 
3.4 Optional genotypic characterisation 
For the optional genotypic characterisation of the AmpC-, ESBL- or carbepenemase producing 
Salmonella test strains, the requested results are the genes encoding AmpC-, ESBL- or 
carbepenemase –production. AmpC-, ESBL- or carbapenemase types included in the test are the 
following: ACC, ACT, CARB, CMY, CTX-M, DHA, FOX, GES, IMP, KPC, MOX, NDM, OXA, 
PER, SCO, SHV, TEM, VEB, and VIM. The database lists the relevant variants of each type.   
When uploading the results in the database, the identified genes will be evaluated against the 
expected results. The results will be evaluated on the detected type (ACC-, ACT-, CARB-, etc.) as 
well as the variant identified.  
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The method used for the genotypic characterisation should be your laboratory’s routine method. 
The expected results listed in the database are those obtained by the EURL-AR.  
4 REPORTING OF RESULTS AND EVALUATION 
Test forms are available for recording your results before you enter them into the interactive web 
database.  
We recommend reading carefully the description reported in paragraph 5 before entering your 
results in the web database.  Results must be submitted no later than December 7th 2018. After 
the deadline when all participants have uploaded results, you will be able to login to the database 
once again, and to view and print an automatically generated report evaluating your results. Results 
in agreement with the expected interpretation are categorised as ‘correct’, while results deviating 
from the expected interpretation are categorised as ‘incorrect’. 
If you experience difficulties in entering your results, please contact us directly.  
All results will be summarized in a report which will be publicly available. The data in the report 
will be presented with laboratory codes. A laboratory code is known to the individual laboratory, 
whereas the complete list of laboratories and their codes is confidential and known only to the 
EURL-AR and the EU Commission. All conclusions will be public. 
If you have questions, please do not hesitate to contact the EQAS Coordinator: 
 
Susanne Karlsmose Pedersen 
National Food Institute,  
Technical University of Denmark 
Kemitorvet, Building 204, DK-2800 Lyngby 
Denmark 
Tel: +45 3588 6601 
E-mail: suska@food.dtu.dk 
5 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE 
Please read carefully this paragraph before entering the web page. 
Remember that you need by your side the completed test forms.  
Enter the EURL-AR EQAS start web page (http://eurl-ar.food.dtu.dk), write your username and 
password (lower-case) and press enter. Your username and password are indicated in the letter 
following your strains. Do not hesitate to contact us if you experience problems with the login. 
You can browse back and forth by using the Home or back keys, but please remember to save your 
inputs before. 
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Click on either “Salmonella test results” or “Campylobacter test results” for input of test results.  
Click on "Start of Data Entry - Methods” 
In the next page, you navigate among fields with the Tab-key and the mouse.  
Complete the fields related to the method used for antimicrobial susceptibility testing and the brand 
of MIC trays, etc.  
When submitting Campylobacter results, fill in the incubation conditions applied for susceptibility 
testing of Campylobacter – 36°C/48h or 42°C/24h. 
Click on "save and go to next page”  
In the data entry pages, you enter the species (for Campylobacter only), the obtained MIC-value 
and the interpretation (R, resistant or S, susceptible) for each Salmonella and Campylobacter strain. 
For Salmonella, remember to also report the results for the ESBL detection tests. 
If you did not test for susceptibility to a given antimicrobial, please leave the field empty. 
Click on "save and go to next page" 
When uploading data on the reference strains, please enter MIC values in µg/ml. Remember to use 
the operator keys to show symbols like “equal to”, etc. 
Click on “save“. 
Review the input pages by browsing through them and make corrections if necessary. Remember to 
save a page if you make corrections. If you press home a page without saving changes, you will see 
an error screen. In this case, click on “save“ to save your results, browse back to the page and then 
continue. 
Please complete the evaluation form. 
Before approving your input, please be sure that you have filled in all the relevant fields as  YOU 
CAN ONLY APPROVE ONCE!  The approval blocks your data entry in the interactive database.  
If you have performed the optional genotypic characterisation: 
Click on “Gene test” and follow the description in the database for upload of the results of the 
optional genotypic characterization. Approve your input. Be sure that you have filled in all the 
results before approval. The approval blocks your data entry in the interactive database, but allows 
you to see the submitted results. 
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APPENDIX 
 
Criteria for interpretation of Salmonella, panel 2 results 
 
 
 
Please refer to: EFSA (European Food Safety Authority) and ECDC (European Centre for Disease 
Prevention and Control), 2017. The European Union summary report on antimicrobial resistance in 
zoonotic and indicator bacteria from humans, animals and food in 2015. EFSA Journal 
2017;15(2):4694, 212 pp. doi:10.2903/j.efsa.2017.4694 (page 43). 
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Salmonella, Campylobacter and genetic characterisation 
 
TEST FORMS 
   
 
 
Name:       
 
Name of laboratory:       
 
Name of institute:       
 
City:       
 
Country:       
 
E-mail:       
 
Fax:       
 
 
Comments:       
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TEST FORM                                                            
 
Does your laboratory have an accreditation for performing Salmonella AST?   Yes     No 
 
Which method did you use for antimicrobial susceptibility testing of Salmonella in this EQAS: 
  Broth microdilution    
 
 Brand of microbroth plates/agar:        
 Incubation conditions:      °C/     h 
 
How many Salmonella isolates does your laboratory annually isolate:       
 
How many Salmonella isolates does your laboratory annually test for antimicrobial susceptibility by 
a MIC method:       
 
Which method was followed for the preparation of the inoculum (please describe) 
• Which standard was followed (TREK, CLSI…)       
• Which solvent was used for the preparation of the 0.5 McFarland solution (water, saline)       
• Please describe in detail how you prepared the dilution of the inoculum (including the volume in 
final MH-dilution and intended dilution level; e.g. diluted 1:1000 by adding 10µl of 0.5 
McFarland solution in 10ml MH broth, for an expected inoculum of 1*105 CFU/ml)       
 
Comments or additional information:       
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TEST FORM          
 
Does your laboratory have an accreditation for Campylobacter AST?  Yes     No 
 
 
Incubation conditions:     36-37ºC / 48h   42ºC / 24h 
 
Method used for antimicrobial susceptibility testing of Campylobacter in this EQAS: 
 Broth microdilution 
 
Brand of microbroth plates/agar:       
 
How many Campylobacter isolates does your laboratory annually isolate:       
How many Campylobacter isolates does your laboratory annually susceptibility test:       
 
Which method was followed for the preparation of the inoculum (please describe) 
• Which standard was followed (TREK, CLSI…)       
• Which solvent was used for the preparation of the 0.5 McFarland solution (water, saline)       
• Please describe in detail how you prepared the dilution of the inoculum (including the volume in 
final MH-dilution and intended dilution level; e.g. diluted 1:1000 by adding 10µl of 0.5 
McFarland solution in 10ml MH broth, for an expected inoculum of 1*105 CFU/ml)       
 
Comments or additional information:       
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TEST FORM                            
 
Strain Antimicrobial  Results and interpretation 
≤ / > MIC-value (μg/ml) S / R 
Salmonella 
EURL S. 13.X 
Ampicillin, AMP                         
Azithromycin, AZI                   
Cefotaxime, FOT                    
Ceftazidime, TAZ                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Colistin, COL                   
Gentamicin, GEN                    
Meropenem, MERO                   
Nalidixic acid, NAL                    
Sulfamethoxazole, SMX                    
Tetracycline, TET                    
Tigecycline, TGC                   
Trimethoprim, TMP                    
 
All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be 
included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or 
carbapenemase production. See further description in the protocol section ‘3.3.1 Salmonella’.                                                     
 
Strain Antimicrobial  Results and interpretation 
≤ / > MIC-value (μg/ml) S / R 
Salmonella 
EURL S. 13.X 
Cefepime, FEP                   
Cefotaxime, FOT                   
Cefotaxime + clavulanic acid (F/C)                   
Cefoxitin, FOX                   
Ceftazidime, TAZ                   
Ceftazidime+ clavulanic acid (T/C)                   
Ertapenem, ETP                   
Imipenem, IMI                   
Meropenem, MERO                   
Temocillin, TRM                   
 
Interpretation of PANEL 2 results: 
 Presumptive ESBL 
 Presumptive ESBL+ AmpC 
 Presumptive AmpC 
 Presumptive Carbapenemase 
 
 Other phenotype 
 Susceptible 
 
Comments (include optional genotype or other results):       
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TEST FORM                                                            
 
Antimicrobial susceptibility testing of reference strain E. coli ATCC 25922 
 
 
 
Antimicrobial  
 
MIC-value (μg/ml) 
1st panel 
 
 
Ampicillin, AMP        
Azithromycin, AZI       
Cefotaxime, FOT       
Ceftazidime, TAZ       
Chloramphenicol, CHL       
Ciprofloxacin, CIP       
Colistin, COL       
Gentamicin, GEN       
Meropenem, MERO       
Nalidixic acid, NAL       
Sulfamethoxazole, SMX*       
Tetracycline, TET       
Tigecycline, TGC       
Trimethoprim, TMP       
2nd panel Cefepime, FEP       
Cefotaxime, FOT       
Cefotaxime + clavulanic acid (F/C)       
Cefoxitin, FOX       
Ceftazidime, TAZ       
Ceftazidime+ clavulanic acid (T/C)       
Ertapenem, ETP       
Imipenem, IMI       
Meropenem, MERO       
Temocillin, TRM       
* for the testing of the E. coli ATCC25922 reference strain, sulfamethoxazole and sulfisoxazole, are 
regarded as comparable, i.e. the obtained MIC-value from the testing of sulfamethoxazole will be evaluated 
against the acceptance range listed in CLSI M100 for sulfisoxazole (CLSI M100, Table 3). 
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TEST FORM                                                           
Strain Antimicrobial  Interpretation 
MIC-value (μg/ml) S / R 
Campylobacter 
EURL C-13.X 
 
     C. jejuni 
 
     C. coli 
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic acid             
Streptomycin             
Tetracycline             
Campylobacter 
EURL C-13.X 
 
     C. jejuni 
 
     C. coli 
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic acid             
Streptomycin             
Tetracycline             
Campylobacter 
EURL C-13.X 
 
     C. jejuni 
 
     C. coli 
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic acid             
Streptomycin             
Tetracycline             
Campylobacter 
EURL C-13.X 
 
     C. jejuni 
 
     C. coli 
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic acid             
Streptomycin             
Tetracycline             
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TEST FORM                                                           
 
Susceptibility testing of Campylobacter jejuni reference strain ATCC 33560 
 
Strain 
 
 
 
Antimicrobial  
 
MIC-value (μg/ml) 
36 °C/48 hours 
 
42 °C/24 hours 
 
 
C. jejuni ATCC 33560 
 
Ciprofloxacin             
Erythromycin             
Nalidixic acid             
Tetracycline             
 
 
  
For Agar dilution: 
 
 Susceptibility testing of Campylobacter jejuni reference strain ATCC 33560 
 
Strain 
 
 
 
Antimicrobial  
 
MIC-value (μg/ml) 
 
C. jejuni ATCC 33560 
 
 
Ciprofloxacin       
 
Erythromycin        
 
Gentamicin       
Nalidixic acid        
Tetracycline       
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TEST FORM – genotypic characterisation                                                           
 
Genotypic characterisation of the test strains 
 
Strain code:  
      
Method used:        
If PCR-methods, additional information should be given below 
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Comments:       
 
 
The 25th EURL-AR Proficiency Test Salmonella, Campylobacter and genotypic characterisation (2018), final version, 1 ed.
EU Reference Laboratory for Antimicrobial Resistance  
External Quality Assurance System (EQAS) 
Instructions for Opening and Reviving Lyophilised Cultures       G00-06-001/01.12.2014 
Page 1 of 1 
INSTRUCTIONS FOR OPENING AND REVIVING 
LYOPHILISED CULTURES 
Instructions adjusted from Czech Collection of Microorganisms (CCM) document ’Instructions for 
Opening and Reviving of Freeze-Dried Bacteria and Fungi’ available on http://www.sci.muni.cz.  
Lyophilised cultures are supplied in vacuum-sealed ampoules. Care should be taken in opening the 
ampoule. All instructions given below should be followed closely to ensure the safety of the person 
who opens the ampoule and to prevent contamination of the culture. 
a. Check the number of the culture on the label inside the ampoule
b. Make a file cut on the ampoule near the middle of the plug (see Figure 1)
c. Disinfect the ampoule with alcohol-dampened gauze or alcohol-dampened cotton wool from
just below the plug to the pointed end
d. Apply a red-hot glass rod to the file cut to crack the glass and allow air to enter slowly into
the ampoule
e. Remove the pointed end of the ampoule into disinfectant
f. Add about 0.3 ml appropriate broth to the dried suspension using a sterile Pasteur pipette
and mix carefully to avoid creating aerosols. Transfer the contents to one or more suitable
solid and /or liquid media
g. Incubate the inoculated medium at appropriate conditions for several days
h. Autoclave or disinfect effectively the used Pasteur pipette, the plug and all the remains of
the original ampoule before discarding
Notes:  
 Cultures should be grown on media and under conditions as recommended in the CCM
catalogue (see http://www.sci.muni.cz)
 Cultures may need at least one subculturing before they can be optimally used in experiments
 Unopened ampoules should be kept in a dark and cool place!
Figure 1: from CCM document ’Instructions for Opening 
and Reviving of Freeze-Dried Bacteria and Fungi’ available 
on http://www.sci.muni.cz 
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SUBCULTURE AND MAINTENANCE OF 
QUALITY CONTROL STRAINS 
1 PURPOSE AND REFERENCES  
Improper storage and repeated subculturing of bacteria can produce alterations in antimicrobial 
susceptibility test results. The Clinical and Laboratory Standards Institute (CLSI) has published 
guidelines for Quality Control (QC) stock culture maintenance to ensure consistent antimicrobial 
susceptibility test (AST) results.  
The following can be regarded as a summary of information that should be followed for 
subculturing and maintaining QC-strains when performing AST by broth dilution methods. For full 
information related to this subject, the following standards are relevant: M100 (Performance 
Standards for Antimicrobial Susceptibility Testing) and M7 (Methods for Dilution Antimicrobial 
Susceptibility Test for Bacteria That Grow Aerobically; Approved Standard). 
2 DEFINITION OF TERMS 
Reference Culture: A reference culture is a microorganism preparation that is acquired from a 
culture type collection.  
Reference Stock Culture: A reference stock culture is a microorganism preparation that is derived 
from a reference culture. Guidelines and standards outline how reference stock cultures must be 
processed and stored.  
Working Stock Cultures: A working stock culture is growth derived from a reference stock culture. 
Guidelines and standards outline how working stock cultures must be processed and how often they 
can be subcultured.  
Subcultures (Passages): A subculture is simply the transfer of established microorganism growth on 
media to fresh media. The subsequent growth on the fresh media constitutes a subculture or 
passage. Growing a reference culture or reference stock culture from its preserved status (frozen or 
lyophilized) is not a subculture. The preserved microorganism is not in a stage of established 
growth until it is thawed or hydrated and grown for the first time. 
3 IMPORTANT CONSIDERATIONS 
 Do not use disc diffusion strains for MIC determination.
 Obtain QC strains from a reliable source such as ATCC.
 CLSI requires that QC be performed either on the same day or weekly (after QC-validation).
 Any changes in materials or procedure must be validated with QC before implemented
 For example: Agar and broth methods may give different QC ranges for drugs such as
glycopeptides, aminoglycosides and macrolides.
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 Periodically perform colony counts to check the inoculum preparation procedure.
 Ideally, test values should be in the middle of the acceptable range.
 Graphing QC data points over time can help identify changes in data helpful for
troubleshooting problems.
4 STORAGE OF REFERENCE STRAINS 
Preparation of stock cultures 
 Use a suitable stabilizer such as 50% fetal calf serum in broth, 10-15% glycerol in tryptic
soy broth, defibrinated sheep blood or skim milk to prepare multiple aliquots.
 Store at -20°C, -70°C or liquid nitrogen (alternatively, freeze dry.)
 Before using rejuvenated strains for QC, subculture to check for purity and viability.
Working cultures 
 Set up on agar slants with appropriate medium, store at 4-8°C and subculture weekly.
 Replace the working strain with a stock culture at least monthly.
 If a change in the organisms inherent susceptibility occurs, obtain a fresh stock culture or a
new strain from a reference culture collection e.g. ATCC.
5 FREQUENCY OF TESTING 
Weekly vs. daily testing  
Weekly testing is possible if the laboratory can demonstrate satisfactory performance with daily 
testing according to the descriptions in the CLSI guidelines. 
 Documentation showing reference strain results from 20 or 30 consecutive test days were
within the acceptable range.
 For each antimicrobial/organism combination, no more one out of 20 or three out of 30 MIC
values may be outside the acceptable range.
When the above are fulfilled, each quality control strain may be tested once a week and whenever 
any reagent component is changed. 
Corrective Actions  
If an MIC is outside the range in weekly testing, corrective action is required as follows: 
 Repeat the test if there is an obvious error e.g. wrong strain or incubation conditions used
 If there is no obvious error, return to daily control testing
If five acceptable QC results are available, no additional days of QC-testing are needed. 
If the problem cannot be resolved, continue daily testing until the errors are identified. 
Repeat the 30 days validation before resuming weekly testing. 
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Quality Control ranges for ATCC reference strains
Antimicrobial Microbroth                (36-37°C/48h)
Microbroth 
(42°C/24h)
Agar dilution     
(36-37°C/48h)
Agar dilution     
(42°C/24h)
Ciprofloxacin, CIP 0.06-0.25 0.03-0.12 0.12-1 0.06-0.5
Erythromycin, ERY 0.5-2 0.25-2 1-8 1-4
Gentamicin, GEN 0.5-2 0.25-2 0.5-2 0.5-4
Nalidixic acid, NAL 4-16 4-16 None None
Tetracycline, TET 0.25-2 0.25-1 None None
E. coli ATCC 25922
Antimicrobial MIC
Ampicillin, AMP 2-8
Azithromycin, AZI none
Cefepime, FEP 0.016-0.12
Cefotaxime, FOT 0.03-0.12
Cefotaxime + clavulanic acid, F/C none
Cefoxitin, FOX 2-8
Ceftazidime, TAZ 0.06-0.5
Ceftazidime + clavulanic acid, T/C none
Chloramphenicol, CHL 2-8
Ciprofloxacin, CIP 0.004-0.016
Colistin, COL 0.25-2
Ertapenem, ETP 0.004-0.016
Gentamicin, GEN 0.25-1
Imipenem, IMI 0.06-0.25
Meropenem, MERO 0.008-0.06
Nalidixic acid, NAL 1-4
Sulfamethoxazole, SMX 8-32
Temocillin, TRM none
Tetracycline, TET 0.5-2
Campylobacter jejuni ATCC 33560
Ranges are according to CLSI (VET06, 1st ed.) 
Tigecycline, TGC 0.03-0.25
Trimethoprim, TMP 0.5-2
MIC ranges and disc diffusion ranges are according to CLSI M100 28th edition
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Test results from the reference strain E. coli ATCC 25922 obtained by microbroth dilution
Lab no. Panel Antimicrobial Operator Value Low limit High limit Mark Temperature Time
2 1 Ampicillin = 8 2 8 1 35±1 18-24
2 1 Cefotaxime <= 0.25 0.03 0.12 1 35±1 18-24
2 1 Ceftazidime <= 0.5 0.06 0.5 1 35±1 18-24
2 1 Chloramphenicol <= 8 2 8 1 35±1 18-24
2 1 Ciprofloxacin <= 0.015 0.004 0.016 1 35±1 18-24
2 1 Colistin <= 1 0.25 2 1 35±1 18-24
2 1 Gentamicin <= 0.5 0.25 1 1 35±1 18-24
2 1 Meropenem <= 0.03 0.008 0.06 1 35±1 18-24
2 1 Nalidixic acid <= 4 1 4 1 35±1 18-24
2 1 Sulfamethoxazole = 32 8 32 1 35±1 18-24
2 1 Tetracycline <= 2 0.5 2 1 35±1 18-24
2 1 Tigecycline <= 0.25 0.03 0.25 1 35±1 18-24
2 1 Trimethoprim = 0.5 0.5 2 1 35±1 18-24
2 2 Cefepime <= 0.06 0.016 0.12 1 35±1 18-24
2 2 Cefotaxime <= 0.25 0.03 0.12 1 35±1 18-24
2 2 Cefoxitin = 8 2 8 1 35±1 18-24
2 2 Ceftazidime = 0.5 0.06 0.5 1 35±1 18-24
2 2 Ertapenem <= 0.015 0.004 0.016 1 35±1 18-24
2 2 Imipenem = 0.25 0.06 0.25 1 35±1 18-24
2 2 Meropenem <= 0.03 0.008 0.06 1 35±1 18-24
4 1 Ampicillin = 4 2 8 1 37°C 24
4 1 Cefotaxime <= 0.25 0.03 0.12 1 37°C 24
4 1 Ceftazidime <= 0.5 0.06 0.5 1 37°C 24
4 1 Chloramphenicol <= 8 2 8 1 37°C 24
4 1 Ciprofloxacin <= 0.015 0.004 0.016 1 37°C 24
4 1 Colistin <= 1 0.25 2 1 37°C 24
4 1 Gentamicin <= 0.05 0.25 1 0 37°C 24
4 1 Meropenem <= 0.03 0.008 0.06 1 37°C 24
4 1 Nalidixic acid <= 4 1 4 1 37°C 24
4 1 Sulfamethoxazole = 32 8 32 1 37°C 24
4 1 Tetracycline <= 2 0.5 2 1 37°C 24
4 1 Tigecycline = 0.5 0.03 0.25 0 37°C 24
4 1 Trimethoprim = 1 0.5 2 1 37°C 24
4 2 Cefepime <= 0.06 0.016 0.12 1 37°C 24
4 2 Cefotaxime <= 0.25 0.03 0.12 1 37°C 24
4 2 Cefoxitin = 2 2 8 1 37°C 24
4 2 Ceftazidime = 0.5 0.06 0.5 1 37°C 24
4 2 Ertapenem <= 0.015 0.004 0.016 1 37°C 24
4 2 Imipenem <= 0.12 0.06 0.25 1 37°C 24
4 2 Meropenem <= 0.03 0.008 0.06 1 37°C 24
6 1 Ampicillin = 4 2 8 1 35 18
6 1 Cefotaxime <= 0.25 0.03 0.12 1 35 18
6 1 Ceftazidime <= 0.5 0.06 0.5 1 35 18
6 1 Chloramphenicol <= 8 2 8 1 35 18
6 1 Ciprofloxacin <= 0.015 0.004 0.016 1 35 18
6 1 Colistin <= 1 0.25 2 1 35 18
6 1 Gentamicin <= 0.5 0.25 1 1 35 18
6 1 Meropenem <= 0.03 0.008 0.06 1 35 18
6 1 Nalidixic acid <= 4 1 4 1 35 18
6 1 Sulfamethoxazole = 32 8 32 1 35 18
6 1 Tetracycline <= 2 0.5 2 1 35 18
6 1 Tigecycline <= 0.25 0.03 0.25 1 35 18
6 1 Trimethoprim = 1 0.5 2 1 35 18
6 2 Cefepime <= 0.06 0.016 0.12 1 35 18
6 2 Cefotaxime <= 0.25 0.03 0.12 1 35 18
6 2 Cefoxitin = 4 2 8 1 35 18
6 2 Ceftazidime <= 0.25 0.06 0.5 1 35 18
6 2 Ertapenem <= 0.015 0.004 0.016 1 35 18
6 2 Imipenem = 0.25 0.06 0.25 1 35 18
6 2 Meropenem <= 0.03 0.008 0.06 1 35 18
9 1 Ampicillin = 4 2 8 1 35+-1 20
9 1 Ceftazidime <= 0.5 0.06 0.5 1 35+-1 20
9 1 Chloramphenicol <= 8 2 8 1 35+-1 20
9 1 Ciprofloxacin <= 0.015 0.004 0.016 1 35+-1 20
9 1 Colistin <= 1 0.25 2 1 35+-1 20
9 1 Gentamicin <= 0.5 0.25 1 1 35+-1 20
9 1 Meropenem <= 0.03 0.008 0.06 1 35+-1 20
9 1 Nalidixic acid <= 4 1 4 1 35+-1 20
9 1 Sulfamethoxazole = 16 8 32 1 35+-1 20
9 1 Tetracycline <= 2 0.5 2 1 35+-1 20
9 1 Tigecycline <= 0.25 0.03 0.25 1 35+-1 20
9 1 Trimethoprim = 1 0.5 2 1 35+-1 20
9 2 Cefepime <= 0.06 0.016 0.12 1 35+-1 20
9 2 Cefoxitin = 4 2 8 1 35+-1 20
9 2 Ceftazidime <= 0.25 0.06 0.5 1 35+-1 20
9 2 Ertapenem <= 0.015 0.004 0.016 1 35+-1 20
9 2 Imipenem <= 0.12 0.06 0.25 1 35+-1 20
9 2 Meropenem <= 0.03 0.008 0.06 1 35+-1 20
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Lab no. Panel Antimicrobial Operator Value Low limit High limit Mark Temperature Time
11 1 Ampicillin = 4 2 8 1 37 20
11 1 Cefotaxime <= 0.25 0.03 0.12 1 37 20
11 1 Ceftazidime <= 0.5 0.06 0.5 1 37 20
11 1 Chloramphenicol <= 8 2 8 1 37 20
11 1 Ciprofloxacin <= 0.015 0.004 0.016 1 37 20
11 1 Colistin <= 1 0.25 2 1 37 20
11 1 Gentamicin = 1 0.25 1 1 37 20
11 1 Meropenem <= 0.03 0.008 0.06 1 37 20
11 1 Nalidixic acid <= 4 1 4 1 37 20
11 1 Sulfamethoxazole = 16 8 32 1 37 20
11 1 Tetracycline <= 2 0.5 2 1 37 20
11 1 Tigecycline <= 0.25 0.03 0.25 1 37 20
11 1 Trimethoprim = 0.5 0.5 2 1 37 20
11 2 Cefepime <= 0.06 0.016 0.12 1 37 20
11 2 Cefotaxime <= 0.25 0.03 0.12 1 37 20
11 2 Cefoxitin = 4 2 8 1 37 20
11 2 Ceftazidime <= 0.25 0.06 0.5 1 37 20
11 2 Ertapenem <= 0.015 0.004 0.016 1 37 20
11 2 Imipenem <= 0.12 0.06 0.25 1 37 20
11 2 Meropenem <= 0.03 0.008 0.06 1 37 20
12 1 Ampicillin = 4 2 8 1 35 18
12 1 Cefotaxime <= 0.25 0.03 0.12 1 35 18
12 1 Ceftazidime <= 0.5 0.06 0.5 1 35 18
12 1 Chloramphenicol <= 8 2 8 1 35 18
12 1 Ciprofloxacin <= 0.015 0.004 0.016 1 35 18
12 1 Colistin <= 1 0.25 2 1 35 18
12 1 Gentamicin <= 0.5 0.25 1 1 35 18
12 1 Meropenem <= 0.03 0.008 0.06 1 35 18
12 1 Nalidixic acid <= 4 1 4 1 35 18
12 1 Sulfamethoxazole = 16 8 32 1 35 18
12 1 Tetracycline <= 2 0.5 2 1 35 18
12 1 Tigecycline <= 0.25 0.03 0.25 1 35 18
12 1 Trimethoprim = 0.5 0.5 2 1 35 18
12 2 Cefepime <= 0.06 0.016 0.12 1 35 18
12 2 Cefotaxime <= 0.25 0.03 0.12 1 35 18
12 2 Cefoxitin = 4 2 8 1 35 18
12 2 Ceftazidime = 0.5 0.06 0.5 1 35 18
12 2 Ertapenem <= 0.015 0.004 0.016 1 35 18
12 2 Imipenem <= 0.12 0.06 0.25 1 35 18
12 2 Meropenem <= 0.03 0.008 0.06 1 35 18
16 1 Ampicillin = 4 2 8 1 35 18-24
16 1 Cefotaxime <= 0.25 0.03 0.12 1 35 18-24
16 1 Ceftazidime <= 0.5 0.06 0.5 1 35 18-24
16 1 Chloramphenicol <= 8 2 8 1 35 18-24
16 1 Ciprofloxacin <= 0.015 0.004 0.016 1 35 18-24
16 1 Colistin <= 1 0.25 2 1 35 18-24
16 1 Gentamicin <= 0.5 0.25 1 1 35 18-24
16 1 Meropenem <= 0.03 0.008 0.06 1 35 18-24
16 1 Nalidixic acid <= 4 1 4 1 35 18-24
16 1 Sulfamethoxazole = 32 8 32 1 35 18-24
16 1 Tetracycline <= 2 0.5 2 1 35 18-24
16 1 Tigecycline <= 0.25 0.03 0.25 1 35 18-24
16 1 Trimethoprim = 0.5 0.5 2 1 35 18-24
16 2 Cefepime <= 0.06 0.016 0.12 1 35 18-24
16 2 Cefotaxime <= 0.25 0.03 0.12 1 35 18-24
16 2 Cefoxitin = 4 2 8 1 35 18-24
16 2 Ceftazidime <= 0.25 0.06 0.5 1 35 18-24
16 2 Ertapenem <= 0.015 0.004 0.016 1 35 18-24
16 2 Imipenem = 0.25 0.06 0.25 1 35 18-24
16 2 Meropenem <= 0.03 0.008 0.06 1 35 18-24
17 1 Ampicillin = 8 2 8 1 36 18-20
17 1 Cefotaxime <= 0.25 0.03 0.12 1 36 18-20
17 1 Ceftazidime <= 0.5 0.06 0.5 1 36 18-20
17 1 Chloramphenicol <= 8 2 8 1 36 18-20
17 1 Ciprofloxacin <= 0.015 0.004 0.016 1 36 18-20
17 1 Colistin <= 1 0.25 2 1 36 18-20
17 1 Gentamicin = 1 0.25 1 1 36 18-20
17 1 Meropenem <= 0.03 0.008 0.06 1 36 18-20
17 1 Nalidixic acid <= 4 1 4 1 36 18-20
17 1 Sulfamethoxazole <= 8 8 32 1 36 18-20
17 1 Tetracycline <= 2 0.5 2 1 36 18-20
17 1 Tigecycline <= 0.25 0.03 0.25 1 36 18-20
17 1 Trimethoprim <= 0.25 0.5 2 0 36 18-20
17 2 Cefepime <= 0.06 0.016 0.12 1 36 18-20
17 2 Cefotaxime <= 0.25 0.03 0.12 1 36 18-20
17 2 Cefoxitin = 4 2 8 1 36 18-20
17 2 Ceftazidime = 0.5 0.06 0.5 1 36 18-20
17 2 Ertapenem <= 0.015 0.004 0.016 1 36 18-20
17 2 Imipenem = 0.25 0.06 0.25 1 36 18-20
17 2 Meropenem <= 0.03 0.008 0.06 1 36 18-20
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18 1 Ampicillin = 2 2 8 1 35 18
18 1 Cefotaxime <= 0.25 0.03 0.12 1 35 18
18 1 Ceftazidime <= 0.5 0.06 0.5 1 35 18
18 1 Chloramphenicol <= 8 2 8 1 35 18
18 1 Ciprofloxacin <= 0.015 0.004 0.016 1 35 18
18 1 Colistin <= 1 0.25 2 1 35 18
18 1 Gentamicin <= 0.5 0.25 1 1 35 18
18 1 Meropenem <= 0.03 0.008 0.06 1 35 18
18 1 Nalidixic acid <= 4 1 4 1 35 18
18 1 Sulfamethoxazole = 16 8 32 1 35 18
18 1 Tetracycline <= 2 0.5 2 1 35 18
18 1 Tigecycline <= 0.25 0.03 0.25 1 35 18
18 1 Trimethoprim = 0.5 0.5 2 1 35 18
18 2 Cefepime <= 0.06 0.016 0.12 1 35 18
18 2 Cefotaxime <= 0.25 0.03 0.12 1 35 18
18 2 Cefoxitin = 4 2 8 1 35 18
18 2 Ceftazidime <= 0.25 0.06 0.5 1 35 18
18 2 Ertapenem <= 0.015 0.004 0.016 1 35 18
18 2 Imipenem <= 0.12 0.06 0.25 1 35 18
18 2 Meropenem <= 0.03 0.008 0.06 1 35 18
19 1 Ampicillin = 4 2 8 1 35 18
19 1 Cefotaxime <= 0.25 0.03 0.12 1 35 18
19 1 Ceftazidime <= 0.5 0.06 0.5 1 35 18
19 1 Chloramphenicol <= 8 2 8 1 35 18
19 1 Ciprofloxacin <= 0.015 0.004 0.016 1 35 18
19 1 Colistin <= 1 0.25 2 1 35 18
19 1 Gentamicin <= 0.5 0.25 1 1 35 18
19 1 Meropenem <= 0.03 0.008 0.06 1 35 18
19 1 Nalidixic acid <= 4 1 4 1 35 18
19 1 Sulfamethoxazole = 16 8 32 1 35 18
19 1 Tetracycline <= 2 0.5 2 1 35 18
19 1 Tigecycline <= 0.25 0.03 0.25 1 35 18
19 1 Trimethoprim = 0.5 0.5 2 1 35 18
19 2 Cefepime <= 0.06 0.016 0.12 1 35 18
19 2 Cefotaxime <= 0.25 0.03 0.12 1 35 18
19 2 Cefoxitin = 4 2 8 1 35 18
19 2 Ceftazidime <= 0.25 0.06 0.5 1 35 18
19 2 Ertapenem <= 0.015 0.004 0.016 1 35 18
19 2 Imipenem <= 0.12 0.06 0.25 1 35 18
19 2 Meropenem <= 0.03 0.008 0.06 1 35 18
20 1 Ampicillin = 4 2 8 1 37C +/-1C 20h +/-2h
20 1 Cefotaxime <= 0.25 0.03 0.12 1 37C +/-1C 20h +/-2h
20 1 Ceftazidime <= 0.5 0.06 0.5 1 37C +/-1C 20h +/-2h
20 1 Chloramphenicol <= 8 2 8 1 37C +/-1C 20h +/-2h
20 1 Ciprofloxacin <= 0.015 0.004 0.016 1 37C +/-1C 20h +/-2h
20 1 Colistin <= 1 0.25 2 1 37C +/-1C 20h +/-2h
20 1 Gentamicin <= 0.5 0.25 1 1 37C +/-1C 20h +/-2h
20 1 Meropenem <= 0.03 0.008 0.06 1 37C +/-1C 20h +/-2h
20 1 Nalidixic acid <= 4 1 4 1 37C +/-1C 20h +/-2h
20 1 Sulfamethoxazole = 16 8 32 1 37C +/-1C 20h +/-2h
20 1 Tetracycline <= 2 0.5 2 1 37C +/-1C 20h +/-2h
20 1 Tigecycline <= 0.25 0.03 0.25 1 37C +/-1C 20h +/-2h
20 1 Trimethoprim = 0.5 0.5 2 1 37C +/-1C 20h +/-2h
20 2 Cefepime <= 0.06 0.016 0.12 1 37C +/-1C 20h +/-2h
20 2 Cefotaxime <= 0.25 0.03 0.12 1 37C +/-1C 20h +/-2h
20 2 Cefoxitin = 4 2 8 1 37C +/-1C 20h +/-2h
20 2 Ceftazidime <= 0.25 0.06 0.5 1 37C +/-1C 20h +/-2h
20 2 Ertapenem <= 0.015 0.004 0.016 1 37C +/-1C 20h +/-2h
20 2 Imipenem = 0.25 0.06 0.25 1 37C +/-1C 20h +/-2h
20 2 Meropenem <= 0.03 0.008 0.06 1 37C +/-1C 20h +/-2h
21 1 Ampicillin = 4 2 8 1 36 24
21 1 Cefotaxime <= 0.25 0.03 0.12 1 36 24
21 1 Ceftazidime = 0.5 0.06 0.5 1 36 24
21 1 Chloramphenicol <= 8 2 8 1 36 24
21 1 Ciprofloxacin <= 0.015 0.004 0.016 1 36 24
21 1 Colistin <= 1 0.25 2 1 36 24
21 1 Gentamicin <= 0.5 0.25 1 1 36 24
21 1 Meropenem <= 0.03 0.008 0.06 1 36 24
21 1 Nalidixic acid <= 4 1 4 1 36 24
21 1 Sulfamethoxazole = 16 8 32 1 36 24
21 1 Tetracycline = 2 0.5 2 1 36 24
21 1 Tigecycline <= 0.25 0.03 0.25 1 36 24
21 1 Trimethoprim <= 0.5 0.5 2 1 36 24
21 2 Cefepime <= 0.06 0.016 0.12 1 36 24
21 2 Cefotaxime <= 0.25 0.03 0.12 1 36 24
21 2 Cefoxitin = 4 2 8 1 36 24
21 2 Ceftazidime <= 0.25 0.06 0.5 1 36 24
21 2 Ertapenem <= 0.015 0.004 0.016 1 36 24
21 2 Imipenem <= 0.12 0.06 0.25 1 36 24
21 2 Meropenem <= 0.03 0.008 0.06 1 36 24
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22 1 Ampicillin = 2 2 8 1 36 20
22 1 Cefotaxime <= 0.25 0.03 0.12 1 36 20
22 1 Ceftazidime <= 0.5 0.06 0.5 1 36 20
22 1 Chloramphenicol <= 8 2 8 1 36 20
22 1 Ciprofloxacin <= 0.015 0.004 0.016 1 36 20
22 1 Colistin <= 1 0.25 2 1 36 20
22 1 Gentamicin = 1 0.25 1 1 36 20
22 1 Meropenem <= 0.03 0.008 0.06 1 36 20
22 1 Nalidixic acid <= 4 1 4 1 36 20
22 1 Sulfamethoxazole = 16 8 32 1 36 20
22 1 Tetracycline <= 2 0.5 2 1 36 20
22 1 Tigecycline <= 0.25 0.03 0.25 1 36 20
22 1 Trimethoprim = 0.5 0.5 2 1 36 20
22 2 Cefepime <= 0.06 0.016 0.12 1 36 20
22 2 Cefotaxime <= 0.25 0.03 0.12 1 36 20
22 2 Cefoxitin = 2 2 8 1 36 20
22 2 Ceftazidime <= 0.25 0.06 0.5 1 36 20
22 2 Ertapenem <= 0.015 0.004 0.016 1 36 20
22 2 Imipenem <= 0.12 0.06 0.25 1 36 20
22 2 Meropenem <= 0.03 0.008 0.06 1 36 20
23 1 Ampicillin = 4 2 8 1 - -
23 1 Cefotaxime <= 0.25 0.03 0.12 1 - -
23 1 Ceftazidime <= 0.5 0.06 0.5 1 - -
23 1 Chloramphenicol <= 8 2 8 1 - -
23 1 Ciprofloxacin <= 0.015 0.004 0.016 1 - -
23 1 Colistin <= 1 0.25 2 1 - -
23 1 Gentamicin <= 0.5 0.25 1 1 - -
23 1 Meropenem <= 0.03 0.008 0.06 1 - -
23 1 Nalidixic acid <= 4 1 4 1 - -
23 1 Sulfamethoxazole = 16 8 32 1 - -
23 1 Tetracycline <= 2 0.5 2 1 - -
23 1 Tigecycline <= 0.25 0.03 0.25 1 - -
23 1 Trimethoprim = 0.5 0.5 2 1 - -
23 2 Cefepime <= 0.06 0.016 0.12 1 - -
23 2 Cefotaxime <= 0.25 0.03 0.12 1 - -
23 2 Cefoxitin = 2 2 8 1 - -
23 2 Ceftazidime <= 0.25 0.06 0.5 1 - -
23 2 Ertapenem <= 0.015 0.004 0.016 1 - -
23 2 Imipenem <= 0.12 0.06 0.25 1 - -
23 2 Meropenem <= 0.03 0.008 0.06 1 - -
25 1 Ampicillin = 8 2 8 1 35 16-20
25 1 Cefotaxime <= 0.25 0.03 0.12 1 35 16-20
25 1 Ceftazidime <= 0.5 0.06 0.5 1 35 16-20
25 1 Chloramphenicol <= 8 2 8 1 35 16-20
25 1 Ciprofloxacin <= 0.015 0.004 0.016 1 35 16-20
25 1 Colistin <= 1 0.25 2 1 35 16-20
25 1 Gentamicin = 1 0.25 1 1 35 16-20
25 1 Meropenem <= 0.03 0.008 0.06 1 35 16-20
25 1 Nalidixic acid <= 4 1 4 1 35 16-20
25 1 Sulfamethoxazole <= 8 8 32 1 35 16-20
25 1 Tetracycline <= 2 0.5 2 1 35 16-20
25 1 Tigecycline <= 0.25 0.03 0.25 1 35 16-20
25 1 Trimethoprim = 0.5 0.5 2 1 35 16-20
25 2 Cefepime <= 0.06 0.016 0.12 1 35 16-20
25 2 Cefotaxime <= 0.25 0.03 0.12 1 35 16-20
25 2 Cefoxitin = 2 2 8 1 35 16-20
25 2 Ceftazidime <= 0.25 0.06 0.5 1 35 16-20
25 2 Ertapenem <= 0.015 0.004 0.016 1 35 16-20
25 2 Imipenem <= 0.12 0.06 0.25 1 35 16-20
25 2 Meropenem <= 0.03 0.008 0.06 1 35 16-20
26 1 Ampicillin = 2 2 8 1 37 18
26 1 Cefotaxime <= 0.25 0.03 0.12 1 37 18
26 1 Ceftazidime <= 0.5 0.06 0.5 1 37 18
26 1 Chloramphenicol <= 8 2 8 1 37 18
26 1 Ciprofloxacin <= 0.015 0.004 0.016 1 37 18
26 1 Colistin <= 1 0.25 2 1 37 18
26 1 Gentamicin = 1 0.25 1 1 37 18
26 1 Meropenem <= 0.03 0.008 0.06 1 37 18
26 1 Nalidixic acid <= 4 1 4 1 37 18
26 1 Sulfamethoxazole = 32 8 32 1 37 18
26 1 Tetracycline <= 2 0.5 2 1 37 18
26 1 Tigecycline <= 0.25 0.03 0.25 1 37 18
26 1 Trimethoprim = 0.5 0.5 2 1 37 18
The 25th EURL-AR Proficiency Test Salmonella, Campylobacter and genotypic characterisation (2018), final version, 1 ed.
Appendix 6a, page 5 of 8
Lab no. Panel Antimicrobial Operator Value Low limit High limit Mark Temperature Time
29 1 Ampicillin = 4 2 8 1 - -
29 1 Cefotaxime <= 0.25 0.03 0.12 1 - -
29 1 Ceftazidime <= 0.5 0.06 0.5 1 - -
29 1 Chloramphenicol <= 8 2 8 1 - -
29 1 Ciprofloxacin <= 0.015 0.004 0.016 1 - -
29 1 Colistin <= 1 0.25 2 1 - -
29 1 Gentamicin <= 0.5 0.25 1 1 - -
29 1 Meropenem <= 0.03 0.008 0.06 1 - -
29 1 Nalidixic acid <= 4 1 4 1 - -
29 1 Sulfamethoxazole = 32 8 32 1 - -
29 1 Tetracycline <= 2 0.5 2 1 - -
29 1 Tigecycline <= 0.25 0.03 0.25 1 - -
29 1 Trimethoprim = 1 0.5 2 1 - -
29 2 Cefepime <= 0.06 0.016 0.12 1 - -
29 2 Cefotaxime <= 0.25 0.03 0.12 1 - -
29 2 Cefoxitin = 2 2 8 1 - -
29 2 Ceftazidime = 0.5 0.06 0.5 1 - -
29 2 Ertapenem <= 0.015 0.004 0.016 1 - -
29 2 Imipenem <= 0.12 0.06 0.25 1 - -
29 2 Meropenem <= 0.03 0.008 0.06 1 - -
30 1 Ampicillin = 4 2 8 1 35 20
30 1 Cefotaxime <= 0.25 0.03 0.12 1 35 20
30 1 Ceftazidime <= 0.5 0.06 0.5 1 35 20
30 1 Chloramphenicol <= 8 2 8 1 35 20
30 1 Ciprofloxacin <= 0.015 0.004 0.016 1 35 20
30 1 Colistin <= 1 0.25 2 1 35 20
30 1 Gentamicin <= 0.5 0.25 1 1 35 20
30 1 Meropenem <= 0.03 0.008 0.06 1 35 20
30 1 Nalidixic acid <= 4 1 4 1 35 20
30 1 Sulfamethoxazole = 16 8 32 1 35 20
30 1 Tetracycline <= 2 0.5 2 1 35 20
30 1 Tigecycline <= 0.25 0.03 0.25 1 35 20
30 1 Trimethoprim = 0.5 0.5 2 1 35 20
30 2 Cefepime <= 0.06 0.016 0.12 1 35 20
30 2 Cefotaxime <= 0.25 0.03 0.12 1 35 20
30 2 Cefoxitin = 2 2 8 1 35 20
30 2 Ceftazidime <= 0.25 0.06 0.5 1 35 20
30 2 Ertapenem <= 0.015 0.004 0.016 1 35 20
30 2 Imipenem <= 0.12 0.06 0.25 1 35 20
30 2 Meropenem <= 0.03 0.008 0.06 1 35 20
32 1 Ampicillin = 4 2 8 1 - -
32 1 Cefotaxime <= 0.25 0.03 0.12 1 - -
32 1 Ceftazidime <= 0.5 0.06 0.5 1 - -
32 1 Chloramphenicol <= 8 2 8 1 - -
32 1 Ciprofloxacin <= 0.15 0.004 0.016 1 - -
32 1 Colistin <= 1 0.25 2 1 - -
32 1 Gentamicin <= 0.5 0.25 1 1 - -
32 1 Meropenem <= 0.03 0.008 0.06 1 - -
32 1 Nalidixic acid <= 4 1 4 1 - -
32 1 Sulfamethoxazole = 32 8 32 1 - -
32 1 Tetracycline <= 2 0.5 2 1 - -
32 1 Tigecycline <= 0.25 0.03 0.25 1 - -
32 1 Trimethoprim = 0.5 0.5 2 1 - -
32 2 Cefotaxime <= 0.25 0.03 0.12 1 - -
32 2 Cefoxitin = 2 2 8 1 - -
32 2 Ceftazidime <= 0.25 0.06 0.5 1 - -
32 2 Ertapenem <= 0.015 0.004 0.016 1 - -
32 2 Imipenem <= 0.12 0.06 0.25 1 - -
32 2 Meropenem <= 0.03 0.008 0.06 1 - -
33 1 Ampicillin = 4 2 8 1 35 16-18
33 1 Cefotaxime <= 0.25 0.03 0.12 1 35 16-18
33 1 Ceftazidime <= 0.5 0.06 0.5 1 35 16-18
33 1 Chloramphenicol <= 8 2 8 1 35 16-18
33 1 Ciprofloxacin <= 0.015 0.004 0.016 1 35 16-18
33 1 Colistin <= 1 0.25 2 1 35 16-18
33 1 Gentamicin <= 0.5 0.25 1 1 35 16-18
33 1 Meropenem <= 0.03 0.008 0.06 1 35 16-18
33 1 Nalidixic acid <= 4 1 4 1 35 16-18
33 1 Sulfamethoxazole = 32 8 32 1 35 16-18
33 1 Tetracycline <= 2 0.5 2 1 35 16-18
33 1 Tigecycline <= 0.25 0.03 0.25 1 35 16-18
33 1 Trimethoprim = 0.5 0.5 2 1 35 16-18
33 2 Cefepime <= 0.06 0.016 0.12 1 35 16-18
33 2 Cefotaxime <= 0.25 0.03 0.12 1 35 16-18
33 2 Cefoxitin = 2 2 8 1 35 16-18
33 2 Ceftazidime <= 0.25 0.06 0.5 1 35 16-18
33 2 Ertapenem <= 0.015 0.004 0.016 1 35 16-18
33 2 Imipenem <= 0.12 0.06 0.25 1 35 16-18
33 2 Meropenem <= 0.03 0.008 0.06 1 35 16-18
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34 1 Ampicillin = 4 2 8 1 37 18-24
34 1 Cefotaxime <= 0.25 0.03 0.12 1 37 18-24
34 1 Ceftazidime <= 0.5 0.06 0.5 1 37 18-24
34 1 Chloramphenicol <= 8 2 8 1 37 18-24
34 1 Ciprofloxacin <= 0.015 0.004 0.016 1 37 18-24
34 1 Colistin <= 1 0.25 2 1 37 18-24
34 1 Gentamicin = 1 0.25 1 1 37 18-24
34 1 Meropenem <= 0.03 0.008 0.06 1 37 18-24
34 1 Nalidixic acid <= 4 1 4 1 37 18-24
34 1 Sulfamethoxazole = 16 8 32 1 37 18-24
34 1 Tetracycline <= 2 0.5 2 1 37 18-24
34 1 Tigecycline <= 0.25 0.03 0.25 1 37 18-24
34 1 Trimethoprim = 0.5 0.5 2 1 37 18-24
34 2 Cefepime <= 0.06 0.016 0.12 1 37 18-24
34 2 Cefotaxime <= 0.25 0.03 0.12 1 37 18-24
34 2 Cefoxitin = 4 2 8 1 37 18-24
34 2 Ceftazidime <= 0.25 0.06 0.5 1 37 18-24
34 2 Ertapenem <= 0.015 0.004 0.016 1 37 18-24
34 2 Imipenem = 0.25 0.06 0.25 1 37 18-24
34 2 Meropenem <= 0.03 0.008 0.06 1 37 18-24
36 1 Ampicillin = 4 2 8 1 35 18-24
36 1 Cefotaxime <= 0.25 0.03 0.12 1 35 18-24
36 1 Ceftazidime <= 0.5 0.06 0.5 1 35 18-24
36 1 Chloramphenicol <= 8 2 8 1 35 18-24
36 1 Ciprofloxacin <= 0.015 0.004 0.016 1 35 18-24
36 1 Colistin <= 1 0.25 2 1 35 18-24
36 1 Gentamicin <= 0.5 0.25 1 1 35 18-24
36 1 Meropenem <= 0.03 0.008 0.06 1 35 18-24
36 1 Nalidixic acid <= 4 1 4 1 35 18-24
36 1 Sulfamethoxazole = 16 8 32 1 35 18-24
36 1 Tetracycline <= 2 0.5 2 1 35 18-24
36 1 Tigecycline <= 0.25 0.03 0.25 1 35 18-24
36 1 Trimethoprim = 1 0.5 2 1 35 18-24
36 2 Cefepime <= 0.06 0.016 0.12 1 35 18-24
36 2 Cefotaxime <= 0.25 0.03 0.12 1 35 18-24
36 2 Cefoxitin = 4 2 8 1 35 18-24
36 2 Ceftazidime <= 0.25 0.06 0.5 1 35 18-24
36 2 Ertapenem <= 0.015 0.004 0.016 1 35 18-24
36 2 Imipenem = 0.25 0.06 0.25 1 35 18-24
36 2 Meropenem <= 0.03 0.008 0.06 1 35 18-24
37 1 Ampicillin = 4 2 8 1 37 18-24
37 1 Cefotaxime <= 0.25 0.03 0.12 1 37 18-24
37 1 Ceftazidime <= 0.5 0.06 0.5 1 37 18-24
37 1 Chloramphenicol <= 8 2 8 1 37 18-24
37 1 Ciprofloxacin <= 0.015 0.004 0.016 1 37 18-24
37 1 Colistin <= 1 0.25 2 1 37 18-24
37 1 Gentamicin = 1 0.25 1 1 37 18-24
37 1 Meropenem <= 0.03 0.008 0.06 1 37 18-24
37 1 Nalidixic acid <= 4 1 4 1 37 18-24
37 1 Sulfamethoxazole = 16 8 32 1 37 18-24
37 1 Tetracycline <= 2 0.5 2 1 37 18-24
37 1 Tigecycline <= 0.25 0.03 0.25 1 37 18-24
37 1 Trimethoprim = 0.5 0.5 2 1 37 18-24
39 1 Ampicillin = 8 2 8 1 35 18-24
39 1 Cefotaxime <= 0.25 0.03 0.12 1 35 18-24
39 1 Ceftazidime <= 0.5 0.06 0.5 1 35 18-24
39 1 Chloramphenicol <= 8 2 8 1 35 18-24
39 1 Ciprofloxacin <= 0.015 0.004 0.016 1 35 18-24
39 1 Colistin <= 1 0.25 2 1 35 18-24
39 1 Gentamicin <= 0.5 0.25 1 1 35 18-24
39 1 Meropenem <= 0.03 0.008 0.06 1 35 18-24
39 1 Nalidixic acid <= 4 1 4 1 35 18-24
39 1 Sulfamethoxazole = 32 8 32 1 35 18-24
39 1 Tetracycline <= 2 0.5 2 1 35 18-24
39 1 Tigecycline <= 0.25 0.03 0.25 1 35 18-24
39 1 Trimethoprim = 0.5 0.5 2 1 35 18-24
39 2 Cefepime <= 0.06 0.016 0.12 1 35 18-24
39 2 Cefotaxime <= 0.25 0.03 0.12 1 35 18-24
39 2 Cefoxitin = 2 2 8 1 35 18-24
39 2 Ceftazidime <= 0.25 0.06 0.5 1 35 18-24
39 2 Ertapenem <= 0.015 0.004 0.016 1 35 18-24
39 2 Imipenem = 0.25 0.06 0.25 1 35 18-24
39 2 Meropenem <= 0.03 0.008 0.06 1 35 18-24
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40 1 Ampicillin = 2 2 8 1 37 20
40 1 Cefotaxime = 0.12 0.03 0.12 1 37 20
40 1 Ceftazidime = 0.5 0.06 0.5 1 37 20
40 1 Chloramphenicol = 8 2 8 1 37 20
40 1 Ciprofloxacin = 0.015 0.004 0.016 1 37 20
40 1 Colistin = 1 0.25 2 1 37 20
40 1 Gentamicin = 0.5 0.25 1 1 37 20
40 1 Meropenem = 0.03 0.008 0.06 1 37 20
40 1 Nalidixic acid = 4 1 4 1 37 20
40 1 Sulfamethoxazole = 16 8 32 1 37 20
40 1 Tetracycline = 2 0.5 2 1 37 20
40 1 Tigecycline = 0.25 0.03 0.25 1 37 20
40 1 Trimethoprim = 0.5 0.5 2 1 37 20
40 2 Cefepime = 0.06 0.016 0.12 1 37 20
40 2 Cefotaxime = 0.12 0.03 0.12 1 37 20
40 2 Cefoxitin = 2 2 8 1 37 20
40 2 Ceftazidime = 0.5 0.06 0.5 1 37 20
40 2 Ertapenem = 0.015 0.004 0.016 1 37 20
40 2 Imipenem = 0.12 0.06 0.25 1 37 20
40 2 Meropenem = 0.03 0.008 0.06 1 37 20
41 1 Ampicillin = 2 2 8 1 37 20
41 1 Cefotaxime <= 0.25 0.03 0.12 1 37 20
41 1 Ceftazidime <= 0.5 0.06 0.5 1 37 20
41 1 Chloramphenicol <= 8 2 8 1 37 20
41 1 Ciprofloxacin <= 0.015 0.004 0.016 1 37 20
41 1 Colistin <= 1 0.25 2 1 37 20
41 1 Gentamicin = 1 0.25 1 1 37 20
41 1 Meropenem <= 0.03 0.008 0.06 1 37 20
41 1 Nalidixic acid <= 4 1 4 1 37 20
41 1 Sulfamethoxazole = 16 8 32 1 37 20
41 1 Tetracycline <= 2 0.5 2 1 37 20
41 1 Tigecycline <= 0.25 0.03 0.25 1 37 20
41 1 Trimethoprim <= 0.5 0.5 2 1 37 20
41 2 Cefepime <= 0.06 0.016 0.12 1 37 20
41 2 Cefotaxime <= 0.25 0.03 0.12 1 37 20
41 2 Cefoxitin = 2 2 8 1 37 20
41 2 Ceftazidime <= 0.5 0.06 0.5 1 37 20
41 2 Ertapenem <= 0.015 0.004 0.016 1 37 20
41 2 Imipenem <= 0.12 0.06 0.25 1 37 20
41 2 Meropenem <= 0.03 0.008 0.06 1 37 20
42 1 Ampicillin = 8 2 8 1 37 24
42 1 Cefotaxime <= 0.25 0.03 0.12 1 37 24
42 1 Ceftazidime <= 0.5 0.06 0.5 1 37 24
42 1 Chloramphenicol <= 8 2 8 1 37 24
42 1 Ciprofloxacin <= 0.015 0.004 0.016 1 37 24
42 1 Colistin <= 1 0.25 2 1 37 24
42 1 Gentamicin <= 0.5 0.25 1 1 37 24
42 1 Meropenem <= 0.03 0.008 0.06 1 37 24
42 1 Nalidixic acid <= 4 1 4 1 37 24
42 1 Sulfamethoxazole = 32 8 32 1 37 24
42 1 Tetracycline <= 2 0.5 2 1 37 24
42 1 Tigecycline <= 0.25 0.03 0.25 1 37 24
42 1 Trimethoprim = 1 0.5 2 1 37 24
42 2 Cefepime <= 0.06 0.016 0.12 1 37 24
42 2 Cefotaxime <= 0.25 0.03 0.12 1 37 24
42 2 Cefoxitin = 2 2 8 1 37 24
42 2 Ceftazidime <= 0.25 0.06 0.5 1 37 24
42 2 Ertapenem <= 0.015 0.004 0.016 1 37 24
42 2 Imipenem <= 0.12 0.06 0.25 1 37 24
42 2 Meropenem <= 0.03 0.008 0.06 1 37 24
45 1 Ampicillin = 4 2 8 1 36/37 20
45 1 Cefotaxime <= 0.25 0.03 0.12 1 36/37 20
45 1 Ceftazidime <= 0.5 0.06 0.5 1 36/37 20
45 1 Chloramphenicol <= 8 2 8 1 36/37 20
45 1 Ciprofloxacin <= 0.015 0.004 0.016 1 36/37 20
45 1 Colistin <= 1 0.25 2 1 36/37 20
45 1 Gentamicin <= 0.5 0.25 1 1 36/37 20
45 1 Meropenem <= 0.03 0.008 0.06 1 36/37 20
45 1 Nalidixic acid <= 4 1 4 1 36/37 20
45 1 Sulfamethoxazole <= 8 8 32 1 36/37 20
45 1 Tetracycline <= 2 0.5 2 1 36/37 20
45 1 Tigecycline <= 0.25 0.03 0.25 1 36/37 20
45 1 Trimethoprim = 1 0.5 2 1 36/37 20
45 2 Cefepime <= 0.06 0.016 0.12 1 36/37 20
45 2 Cefotaxime <= 0.25 0.03 0.12 1 36/37 20
45 2 Cefoxitin = 4 2 8 1 36/37 20
45 2 Ceftazidime <= 0.25 0.06 0.5 1 36/37 20
45 2 Ertapenem <= 0.015 0.004 0.016 1 36/37 20
45 2 Imipenem <= 0.12 0.06 0.25 1 36/37 20
45 2 Meropenem <= 0.03 0.008 0.06 1 36/37 20
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56 1 Ampicillin = 2 2 8 1 35 20
56 1 Cefotaxime <= 0.25 0.03 0.12 1 35 20
56 1 Ceftazidime <= 0.5 0.06 0.5 1 35 20
56 1 Chloramphenicol <= 8 2 8 1 35 20
56 1 Ciprofloxacin <= 0.015 0.004 0.016 1 35 20
56 1 Colistin <= 1 0.25 2 1 35 20
56 1 Gentamicin <= 0.5 0.25 1 1 35 20
56 1 Meropenem <= 0.03 0.008 0.06 1 35 20
56 1 Nalidixic acid <= 4 1 4 1 35 20
56 1 Sulfamethoxazole = 32 8 32 1 35 20
56 1 Tetracycline <= 2 0.5 2 1 35 20
56 1 Tigecycline <= 0.25 0.03 0.25 1 35 20
56 1 Trimethoprim = 0.5 0.5 2 1 35 20
56 2 Cefepime <= 0.06 0.016 0.12 1 35 20
56 2 Cefotaxime <= 0.25 0.03 0.12 1 35 20
56 2 Cefoxitin = 4 2 8 1 35 20
56 2 Ceftazidime <= 0.25 0.06 0.5 1 35 20
56 2 Ertapenem <= 0.015 0.004 0.016 1 35 20
56 2 Imipenem <= 0.12 0.06 0.25 1 35 20
56 2 Meropenem <= 0.03 0.008 0.06 1 35 20
59 1 Ampicillin = 2 2 8 1 35 18-24
59 1 Cefotaxime <= 0.25 0.03 0.12 1 35 18-24
59 1 Ceftazidime <= 0.5 0.06 0.5 1 35 18-24
59 1 Chloramphenicol <= 8 2 8 1 35 18-24
59 1 Ciprofloxacin <= 0.015 0.004 0.016 1 35 18-24
59 1 Colistin <= 1 0.25 2 1 35 18-24
59 1 Gentamicin <= 0.5 0.25 1 1 35 18-24
59 1 Meropenem <= 0.03 0.008 0.06 1 35 18-24
59 1 Nalidixic acid <= 4 1 4 1 35 18-24
59 1 Tetracycline <= 2 0.5 2 1 35 18-24
59 1 Tigecycline <= 0.25 0.03 0.25 1 35 18-24
59 1 Trimethoprim <= 0.25 0.5 2 0 35 18-24
59 2 Cefepime <= 0.06 0.016 0.12 1 35 18-24
59 2 Cefotaxime <= 0.25 0.03 0.12 1 35 18-24
59 2 Cefoxitin = 2 2 8 1 35 18-24
59 2 Ceftazidime <= 0.25 0.06 0.5 1 35 18-24
59 2 Ertapenem <= 0.015 0.004 0.016 1 35 18-24
59 2 Imipenem <= 0.12 0.06 0.25 1 35 18-24
59 2 Meropenem <= 0.03 0.008 0.06 1 35 18-24
60 1 Ampicillin = 4 2 8 1 36±1 18-20
60 1 Cefotaxime = 0.25 0.03 0.12 0 36±1 18-20
60 1 Ceftazidime = 0.5 0.06 0.5 1 36±1 18-20
60 1 Chloramphenicol = 8 2 8 1 36±1 18-20
60 1 Ciprofloxacin = 0.015 0.004 0.016 1 36±1 18-20
60 1 Colistin = 1 0.25 2 1 36±1 18-20
60 1 Gentamicin = 0.5 0.25 1 1 36±1 18-20
60 1 Meropenem = 0.03 0.008 0.06 1 36±1 18-20
60 1 Nalidixic acid = 4 1 4 1 36±1 18-20
60 1 Sulfamethoxazole = 8 8 32 1 36±1 18-20
60 1 Tetracycline = 2 0.5 2 1 36±1 18-20
60 1 Tigecycline = 0.25 0.03 0.25 1 36±1 18-20
60 1 Trimethoprim = 0.5 0.5 2 1 36±1 18-20
60 2 Cefepime <= 0.06 0.016 0.12 1 36±1 18-20
60 2 Cefotaxime <= 0.25 0.03 0.12 1 36±1 18-20
60 2 Cefoxitin = 4 2 8 1 36±1 18-20
60 2 Ceftazidime <= 0.25 0.06 0.5 1 36±1 18-20
60 2 Ertapenem <= 0.015 0.004 0.016 1 36±1 18-20
60 2 Imipenem = 0.25 0.06 0.25 1 36±1 18-20
60 2 Meropenem <= 0.03 0.008 0.06 1 36±1 18-20
64 1 Ampicillin = 2 2 8 1 37 18
64 1 Cefotaxime <= 0.25 0.03 0.12 1 37 18
64 1 Ceftazidime <= 0.5 0.06 0.5 1 37 18
64 1 Chloramphenicol <= 8 2 8 1 37 18
64 1 Ciprofloxacin <= 0.015 0.004 0.016 1 37 18
64 1 Colistin <= 1 0.25 2 1 37 18
64 1 Gentamicin = 1 0.25 1 1 37 18
64 1 Meropenem <= 0.03 0.008 0.06 1 37 18
64 1 Nalidixic acid <= 4 1 4 1 37 18
64 1 Sulfamethoxazole = 32 8 32 1 37 18
64 1 Tetracycline <= 2 0.5 2 1 37 18
64 1 Tigecycline <= 0.25 0.03 0.25 1 37 18
64 1 Trimethoprim = 1 0.5 2 1 37 18
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Test results from the reference strain C. jejuni ATCC 33560
Lab no. Antimicrobial Operator Value Low limit High limit Mark Method 36-37ºC/48h 42ºC/24h
2 Ciprofloxacin CIP = 0.25 0.06 0.25 1 MIC X
2 Erythromycin ERY = 1 0.5 2 1 MIC X
2 Gentamicin GEN = 1 0.5 2 1 MIC X
2 Nalidixic acid NAL = 8 4 16 1 MIC X
2 Tetracycline TET = 2 0.25 2 1 MIC X
4 Ciprofloxacin CIP = 0.25 0.06 0.25 1 MIC X
4 Erythromycin ERY = 2 0.5 2 1 MIC X
4 Gentamicin GEN = 0.5 0.5 2 1 MIC X
4 Nalidixic acid NAL = 16 4 16 1 MIC X
4 Tetracycline TET = 4 0.25 2 0 MIC X
6 Ciprofloxacin CIP <= 0.12 0.03 0.125 1 MIC X
6 Erythromycin ERY <= 1 0.25 2 1 MIC X
6 Gentamicin GEN = 1 0.25 2 1 MIC X
6 Nalidixic acid NAL = 8 4 16 1 MIC X
6 Tetracycline TET = 1 0.25 1 1 MIC X
9 Ciprofloxacin CIP = 0.25 0.06 0.25 1 MIC X
9 Erythromycin ERY <= 1 0.5 2 1 MIC X
9 Gentamicin GEN = 0.5 0.5 2 1 MIC X
9 Nalidixic acid NAL = 8 4 16 1 MIC X
9 Tetracycline TET = 1 0.25 2 1 MIC X
11 Ciprofloxacin CIP <= 0.12 0.03 0.125 1 MIC X
11 Erythromycin ERY = 2 0.25 2 1 MIC X
11 Gentamicin GEN = 1 0.25 2 1 MIC X
11 Nalidixic acid NAL = 8 4 16 1 MIC X
11 Tetracycline TET = 1 0.25 1 1 MIC X
12 Ciprofloxacin CIP = 0.25 0.06 0.25 1 MIC X
12 Erythromycin ERY <= 1 0.5 2 1 MIC X
12 Gentamicin GEN = 1 0.5 2 1 MIC X
12 Nalidixic acid NAL = 8 4 16 1 MIC X
12 Tetracycline TET <= 0.5 0.25 2 1 MIC X
14 Ciprofloxacin CIP <= 0.125 0.03 0.125 1 MIC X
14 Erythromycin ERY <= 1 0.25 2 1 MIC X
14 Gentamicin GEN = 0.5 0.25 2 1 MIC X
14 Nalidixic acid NAL = 4 4 16 1 MIC X
14 Tetracycline TET <= 0.5 0.25 1 1 MIC X
17 Ciprofloxacin CIP = 0.25 0.06 0.25 1 MIC X
17 Erythromycin ERY <= 1 0.5 2 1 MIC X
17 Gentamicin GEN = 1 0.5 2 1 MIC X
17 Nalidixic acid NAL = 8 4 16 1 MIC X
17 Tetracycline TET <= 0.5 0.25 2 1 MIC X
18 Ciprofloxacin CIP <= 0.12 0.03 0.125 1 MIC X
18 Erythromycin ERY <= 1 0.25 2 1 MIC X
18 Gentamicin GEN = 0.5 0.25 2 1 MIC X
18 Nalidixic acid NAL = 4 4 16 1 MIC X
18 Tetracycline TET <= 0.5 0.25 1 1 MIC X
19 Ciprofloxacin CIP <= 0.12 0.03 0.125 1 MIC X
19 Erythromycin ERY <= 1 0.25 2 1 MIC X
19 Gentamicin GEN = 0.5 0.25 2 1 MIC X
19 Nalidixic acid NAL = 8 4 16 1 MIC X
19 Tetracycline TET <= 0.5 0.25 1 1 MIC X
20 Ciprofloxacin CIP <= 0.12 0.06 0.25 1 MIC X
20 Erythromycin ERY <= 1 0.5 2 1 MIC X
20 Gentamicin GEN = 1 0.5 2 1 MIC X
20 Nalidixic acid NAL = 8 4 16 1 MIC X
20 Tetracycline TET = 1 0.25 2 1 MIC X
21 Ciprofloxacin CIP = 0.12 0.03 0.125 1 MIC X
21 Erythromycin ERY = 1 0.25 2 1 MIC X
21 Gentamicin GEN = 0.5 0.25 2 1 MIC X
21 Nalidixic acid NAL = 4 4 16 1 MIC X
21 Tetracycline TET = 0.5 0.25 1 1 MIC X
22 Ciprofloxacin CIP <= 0.125 0.03 0.125 1 MIC X
22 Erythromycin ERY <= 1 0.25 2 1 MIC X
22 Gentamicin GEN = 0.5 0.25 2 1 MIC X
22 Nalidixic acid NAL = 4 4 16 1 MIC X
22 Tetracycline TET = 1 0.25 1 1 MIC X
23 Ciprofloxacin CIP = 0.06 0.03 0.125 1 MIC X
23 Erythromycin ERY <= 1 0.25 2 1 MIC X
23 Gentamicin GEN = 1 0.25 2 1 MIC X
23 Nalidixic acid NAL = 4 4 16 1 MIC X
23 Tetracycline TET = 1 0.25 1 1 MIC X
25 Ciprofloxacin CIP = 0.25 0.06 0.25 1 MIC X
25 Erythromycin ERY = 2 0.5 2 1 MIC X
25 Gentamicin GEN = 0.25 0.5 2 0 MIC X
25 Nalidixic acid NAL = 8 4 16 1 MIC X
25 Tetracycline TET = 2 0.25 2 1 MIC X
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Lab no. Antimicrobial Operator Value Low limit High limit Mark Method 36-37ºC/48h 42ºC/24h
26 Ciprofloxacin CIP <= 0.12 0.06 0.25 1 MIC X
26 Erythromycin ERY <= 1 0.5 2 1 MIC X
26 Gentamicin GEN = 1 0.5 2 1 MIC X
26 Nalidixic acid NAL = 8 4 16 1 MIC X
26 Tetracycline TET = 1 0.25 2 1 MIC X
30 Ciprofloxacin CIP <= 0.12 0.06 0.25 1 MIC X
30 Erythromycin ERY <= 1 0.5 2 1 MIC X
30 Gentamicin GEN = 1 0.5 2 1 MIC X
30 Nalidixic acid NAL = 4 4 16 1 MIC X
30 Tetracycline TET = 2 0.25 2 1 MIC X
32 Ciprofloxacin CIP <= 0.12 0.06 0.25 1 MIC X
32 Erythromycin ERY <= 1 0.5 2 1 MIC X
32 Gentamicin GEN = 1 0.5 2 1 MIC X
32 Nalidixic acid NAL = 8 4 16 1 MIC X
32 Tetracycline TET <= 0.5 0.25 2 1 MIC X
33 Ciprofloxacin CIP <= 0.12 0.06 0.25 1 MIC X
33 Erythromycin ERY <= 1 0.5 2 1 MIC X
33 Gentamicin GEN = 1 0.5 2 1 MIC X
33 Nalidixic acid NAL = 8 4 16 1 MIC X
33 Tetracycline TET <= 0.5 0.25 2 1 MIC X
34 Ciprofloxacin CIP <= 0.12 0.06 0.25 1 MIC X
34 Erythromycin ERY <= 1 0.5 2 1 MIC X
34 Gentamicin GEN = 1 0.5 2 1 MIC X
34 Nalidixic acid NAL = 8 4 16 1 MIC X
34 Tetracycline TET = 1 0.25 2 1 MIC X
36 Ciprofloxacin CIP <= 0.12 0.03 0.125 1 MIC X
36 Erythromycin ERY <= 1 0.25 2 1 MIC X
36 Gentamicin GEN = 0.5 0.25 2 1 MIC X
36 Nalidixic acid NAL = 8 4 16 1 MIC X
36 Tetracycline TET = 1 0.25 1 1 MIC X
37 Ciprofloxacin CIP <= 0.12 0.06 0.25 1 MIC X
37 Erythromycin ERY <= 1 0.5 2 1 MIC X
37 Gentamicin GEN = 0.25 0.5 2 0 MIC X
37 Nalidixic acid NAL = 4 4 16 1 MIC X
37 Tetracycline TET <= 0.5 0.25 2 1 MIC X
39 Ciprofloxacin CIP <= 0.12 0.03 0.125 1 MIC X
39 Erythromycin ERY <= 1 0.25 2 1 MIC X
39 Gentamicin GEN = 0.5 0.25 2 1 MIC X
39 Nalidixic acid NAL = 4 4 16 1 MIC X
39 Tetracycline TET <= 0.5 0.25 1 1 MIC X
40 Ciprofloxacin CIP = 0.12 0.03 0.125 1 MIC X
40 Erythromycin ERY = 1 0.25 2 1 MIC X
40 Nalidixic acid NAL = 8 4 16 1 MIC X
40 Tetracycline TET = 0.5 0.25 1 1 MIC X
41 Ciprofloxacin CIP <= 0.12 0.03 0.125 1 MIC X
41 Erythromycin ERY <= 1 0.25 2 1 MIC X
41 Gentamicin GEN = 1 0.25 2 1 MIC X
41 Nalidixic acid NAL = 8 4 16 1 MIC X
41 Tetracycline TET = 1 0.25 1 1 MIC X
42 Ciprofloxacin CIP = 0.25 0.06 0.25 1 MIC X
42 Erythromycin ERY = 2 0.5 2 1 MIC X
42 Gentamicin GEN = 0.25 0.5 2 0 MIC X
42 Nalidixic acid NAL = 8 4 16 1 MIC X
42 Tetracycline TET = 2 0.25 2 1 MIC X
45 Ciprofloxacin CIP <= 0.12 0.06 0.25 1 MIC X
45 Erythromycin ERY <= 1 0.5 2 1 MIC X
45 Gentamicin GEN = 1 0.5 2 1 MIC X
45 Nalidixic acid NAL = 8 4 16 1 MIC X
45 Tetracycline TET = 2 0.25 2 1 MIC X
56 Ciprofloxacin CIP <= 0.12 0.03 0.125 1 MIC X
56 Erythromycin ERY <= 1 0.25 2 1 MIC X
56 Gentamicin GEN = 0.25 0.25 2 1 MIC X
56 Nalidixic acid NAL = 4 4 16 1 MIC X
56 Tetracycline TET <= 0.5 0.25 1 1 MIC X
59 Ciprofloxacin CIP <= 0.12 0.06 0.25 1 MIC X
59 Erythromycin ERY <= 1 0.5 2 1 MIC X
59 Gentamicin GEN = 1 0.5 2 1 MIC X
59 Nalidixic acid NAL = 8 4 16 1 MIC X
59 Tetracycline TET = 1 0.25 2 1 MIC X
60 Ciprofloxacin CIP = 0.25 0.06 0.25 1 MIC X
60 Erythromycin ERY <= 1 0.5 2 1 MIC X
60 Gentamicin GEN = 1 0.5 2 1 MIC X
60 Nalidixic acid NAL = 8 4 16 1 MIC X
60 Tetracycline TET = 1 0.25 2 1 MIC X
MIC: Microbroth dilution
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Salmonella - expected and obtained interpretation
Antimicrobial Strain Panel Expected % R % S No. correct No. incorrect
EURL S-13.1 Panel 1 R 100 0 32 0
EURL S-13.2 Panel 1 R 100 0 32 0
EURL S-13.3 Panel 1 S 0 100 32 0
EURL S-13.4 Panel 1 R 96.9 3.1 31 1
EURL S-13.5 Panel 1 S 0 100 32 0
EURL S-13.6 Panel 1 R 100 0 32 0
EURL S-13.7 Panel 1 R 100 0 32 0
EURL S-13.8 Panel 1 R 100 0 32 0
EURL S-13.1 Panel 1 S 0 100 24 0
EURL S-13.2 Panel 1 R 100 0 24 0
EURL S-13.3 Panel 1 S 0 100 24 0
EURL S-13.4 Panel 1 S 0 100 24 0
EURL S-13.5 Panel 1 S 0 100 24 0
EURL S-13.6 Panel 1 R 95.8 4.2 23 1
EURL S-13.7 Panel 1 S 0 100 24 0
EURL S-13.8 Panel 1 R 100 0 24 0
EURL S-13.1 Panel 1 R 100 0 32 0
EURL S-13.2 Panel 1 S 0 100 31 0
EURL S-13.3 Panel 1 S 0 100 32 0
EURL S-13.4 Panel 1 R 100 0 32 0
EURL S-13.5 Panel 1 S 0 100 32 0
EURL S-13.6 Panel 1 S 12.5 87.5 28 4
EURL S-13.7 Panel 1 R 100 0 32 0
EURL S-13.8 Panel 1 R 100 0 32 0
EURL S-13.1 Panel 2 R 100 0 32 0
EURL S-13.4 Panel 2 R 100 0 32 0
EURL S-13.6 Panel 2 S 9.7 90.3 28 3
EURL S-13.7 Panel 2 R 100 0 32 0
EURL S-13.8 Panel 2 R 100 0 32 0
EURL S-13.1 Panel 2 S 3.1 96.9 31 1
EURL S-13.4 Panel 2 S 3.1 96.9 31 1
EURL S-13.6 Panel 2 S 12.9 87.1 27 4
EURL S-13.7* Panel 2* S* 35.5* 64.5* 20* 11*
EURL S-13.8 Panel 2 S 3.1 96.9 31 1
EURL S-13.1* Panel 1* R* 61.3* 38.7* 19* 12*
EURL S-13.2 Panel 1 S 0 100 32 0
EURL S-13.3 Panel 1 S 0 100 32 0
EURL S-13.4 Panel 1 S 0 100 32 0
EURL S-13.5 Panel 1 S 0 100 32 0
EURL S-13.6 Panel 1 S 0 100 32 0
EURL S-13.7 Panel 1 R 100 0 32 0
EURL S-13.8 Panel 1 R 100 0 32 0
EURL S-13.1* Panel 2* R* 62.5* 37.5* 20* 12*
EURL S-13.4 Panel 2 S 3.1 96.9 31 1
EURL S-13.6 Panel 2 S 0 100 31 0
EURL S-13.7 Panel 2 R 100 0 32 0
EURL S-13.8 Panel 2 R 100 0 32 0
EURL S-13.1 Panel 1 S 0 100 32 0
EURL S-13.2 Panel 1 S 3.1 96.9 31 1
EURL S-13.3 Panel 1 S 0 100 32 0
EURL S-13.4 Panel 1 S 0 100 32 0
EURL S-13.5 Panel 1 S 0 100 32 0
EURL S-13.6 Panel 1 S 0 100 32 0
EURL S-13.7 Panel 1 R 100 0 32 0
EURL S-13.8 Panel 1 S 0 100 32 0
Azithromycin AZI
Cefotaxime FOT
Cefoxitin FOX
Ampicillin AMP
Chloramphenicol CHL
Ceftazidime TAZ
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Antimicrobial Strain Panel Expected % R % S No. correct No. incorrect
EURL S-13.1 Panel 1 S 0 100 32 0
EURL S-13.2 Panel 1 S 0 100 32 0
EURL S-13.3 Panel 1 S 0 100 32 0
EURL S-13.4 Panel 1 R 93.8 6.2 30 2
EURL S-13.5 Panel 1 S 0 100 32 0
EURL S-13.6 Panel 1 R 96.9 3.1 31 1
EURL S-13.7 Panel 1 S 0 100 32 0
EURL S-13.8 Panel 1 S 0 100 32 0
EURL S-13.1 Panel 1 S 0 100 32 0
EURL S-13.2 Panel 1 S 0 100 32 0
EURL S-13.3 Panel 1 S 0 100 32 0
EURL S-13.4 Panel 1 S 0 100 32 0
EURL S-13.5 Panel 1 R 90.3 9.7 28 3
EURL S-13.6 Panel 1 S 0 100 32 0
EURL S-13.7 Panel 1 S 0 100 32 0
EURL S-13.8 Panel 1 S 0 100 32 0
EURL S-13.1 Panel 2 S 0 100 31 0
EURL S-13.4 Panel 2 S 0 100 32 0
EURL S-13.6 Panel 2 R 100 0 31 0
EURL S-13.7 Panel 2 S 3.1 96.9 31 1
EURL S-13.8 Panel 2 S 0 100 32 0
EURL S-13.1 Panel 1 S 0 100 32 0
EURL S-13.2 Panel 1 S 0 100 32 0
EURL S-13.3 Panel 1 S 0 100 32 0
EURL S-13.4 Panel 1 S 0 100 32 0
EURL S-13.5 Panel 1 S 0 100 32 0
EURL S-13.6 Panel 1 S 0 100 32 0
EURL S-13.7 Panel 1 R 100 0 32 0
EURL S-13.8 Panel 1 R 100 0 32 0
EURL S-13.1 Panel 2 S 0 100 32 0
EURL S-13.4 Panel 2 S 0 100 32 0
EURL S-13.6 Panel 2 S 16.1 83.9 26 5
EURL S-13.7 Panel 2 S 0 100 32 0
EURL S-13.8 Panel 2 S 0 100 32 0
EURL S-13.1 Panel 1 S 0 100 32 0
EURL S-13.2 Panel 1 S 0 100 32 0
EURL S-13.3 Panel 1 S 0 100 32 0
EURL S-13.4 Panel 1 S 0 100 32 0
EURL S-13.5 Panel 1 S 0 100 32 0
EURL S-13.6 Panel 1 R 90.6 9.4 29 3
EURL S-13.7 Panel 1 S 0 100 32 0
EURL S-13.8 Panel 1 S 0 100 32 0
EURL S-13.1 Panel 2 S 0 100 32 0
EURL S-13.4 Panel 2 S 0 100 32 0
EURL S-13.6 Panel 2 R 93.5 6.5 29 2
EURL S-13.7 Panel 2 S 0 100 32 0
EURL S-13.8 Panel 2 S 0 100 32 0
EURL S-13.1 Panel 1 S 0 100 32 0
EURL S-13.2 Panel 1 S 0 100 32 0
EURL S-13.3 Panel 1 S 0 100 32 0
EURL S-13.4 Panel 1 R 100 0 32 0
EURL S-13.5 Panel 1 S 0 100 32 0
EURL S-13.6 Panel 1 R 100 0 32 0
EURL S-13.7 Panel 1 S 0 100 32 0
EURL S-13.8 Panel 1 S 0 100 32 0
Nalidixic acid NAL
Meropenem MER
Imipenem IMI
Gentamicin GEN
Ertapenem ETP
Colistin COL
Ciprofloxacin CIP
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Antimicrobial Strain Panel Expected % R % S No. correct No. incorrect
EURL S-13.1 Panel 1 R 100 0 31 0
EURL S-13.2 Panel 1 S 0 100 31 0
EURL S-13.3 Panel 1 S 12.9 87.1 27 4
EURL S-13.4 Panel 1 S 0 100 31 0
EURL S-13.5 Panel 1 R 100 0 31 0
EURL S-13.6 Panel 1 S 3.2 96.8 30 1
EURL S-13.7 Panel 1 R 100 0 31 0
EURL S-13.8 Panel 1 R 96.8 3.2 30 1
EURL S-13.1 Panel 2 S 0 100 24 0
EURL S-13.4 Panel 2 S 0 100 25 0
EURL S-13.6 Panel 2 R 100 0 25 0
EURL S-13.7 Panel 2 R 95.8 4.2 23 1
EURL S-13.8 Panel 2 S 0 100 24 0
EURL S-13.1 Panel 1 R 100 0 32 0
EURL S-13.2 Panel 1 S 0 100 32 0
EURL S-13.3 Panel 1 S 0 100 32 0
EURL S-13.4 Panel 1 R 100 0 32 0
EURL S-13.5 Panel 1 S 0 100 32 0
EURL S-13.6 Panel 1 S 0 100 32 0
EURL S-13.7 Panel 1 R 100 0 32 0
EURL S-13.8 Panel 1 S 0 100 32 0
EURL S-13.1 Panel 1 S 0 100 32 0
EURL S-13.2 Panel 1 S 0 100 32 0
EURL S-13.3 Panel 1 S 0 100 32 0
EURL S-13.4 Panel 1 S 0 100 32 0
EURL S-13.5 Panel 1 S 0 100 32 0
EURL S-13.6 Panel 1 S 0 100 32 0
EURL S-13.7 Panel 1 S 0 100 32 0
EURL S-13.8 Panel 1 S 0 100 32 0
EURL S-13.1 Panel 1 S 0 100 32 0
EURL S-13.2 Panel 1 S 0 100 32 0
EURL S-13.3 Panel 1 S 0 100 32 0
EURL S-13.4 Panel 1 S 0 100 31 0
EURL S-13.5 Panel 1 R 96.9 3.1 31 1
EURL S-13.6 Panel 1 S 0 100 32 0
EURL S-13.7 Panel 1 R 100 0 32 0
EURL S-13.8 Panel 1 R 96.9 3.1 31 1
*Strain/antimicrobial-combination excluded from the evaluation
Trimethoprim TMP
Tigecycline TGC
Tetracycline TET
Temocillin TRM
Sulfamethoxazole SMX
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Campylobacter  - expected and obtained interpretation
 
Antimicrobial Strain Expected % R % S No. correct No. incorrect
EURL C-13.1 R 100 0 31 0
EURL C-13.2 S 0 100 31 0
EURL C-13.3 R 100 0 30 0
EURL C-13.4 R 100 0 31 0
EURL C-13.5 S 0 100 31 0
EURL C-13.6 R 97 3 29 1
EURL C-13.7 S 0 100 31 0
EURL C-13.8 R 100 0 31 0
EURL C-13.1 S 0 100 31 0
EURL C-13.2 R 100 0 31 0
EURL C-13.3 S 7 93 28 2
EURL C-13.4 R 100 0 31 0
EURL C-13.5 S 0 100 31 0
EURL C-13.6 S 0 100 31 0
EURL C-13.7 R 100 0 31 0
EURL C-13.8 S 0 100 31 0
EURL C-13.1 S 0 100 31 0
EURL C-13.2 S 0 100 31 0
EURL C-13.3 S 0 100 30 0
EURL C-13.4 R 100 0 31 0
EURL C-13.5 S 0 100 31 0
EURL C-13.6 S 0 100 31 0
EURL C-13.7 S 0 100 31 0
EURL C-13.8 S 0 100 31 0
EURL C-13.1 R 97 3 30 1
EURL C-13.2 S 0 100 31 0
EURL C-13.3 R 100 0 30 0
EURL C-13.4 R 100 0 31 0
EURL C-13.5 S 0 100 31 0
EURL C-13.6 S 3 97 29 1
EURL C-13.7 S 0 100 31 0
EURL C-13.8 R 100 0 31 0
EURL C-13.1 S 0 100 31 0
EURL C-13.2 S 0 100 31 0
EURL C-13.3 R 100 0 30 0
EURL C-13.4 R 100 0 31 0
EURL C-13.5 S 0 100 31 0
EURL C-13.6 S 0 100 31 0
EURL C-13.7 R 100 0 31 0
EURL C-13.8 R 100 0 31 0
EURL C-13.1 R 97 3 30 1
EURL C-13.2 S 3 97 30 1
EURL C-13.3 R 100 0 30 0
EURL C-13.4 R 100 0 31 0
EURL C-13.5 S 0 100 31 0
EURL C-13.6 S 3 97 30 1
EURL C-13.7 S 0 100 31 0
EURL C-13.8 S 0 100 31 0
Ciprofloxacin, CIP
Tetracycline, TET
Streptomycin, STR
Nalidixic acid, NAL
Gentamicin, GEN
Erythromycin, ERY
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Deviations - Salmonella
Lab no. Strain Panel Antimicrobial Obtained MIC value
Expected 
MIC-value Obtained interpretation Expected interpretation
4 EURL S-13.3 1 Sulfamethoxazole SMX 512 32 R S
4 EURL S-13.4 1 Ciprofloxacin CIP = 0.25 0.5 S R
4 EURL S-13.6 1 Ciprofloxacin CIP 8 8 S R
4 EURL S-13.6 1 Meropenem MER = 0.12 0.5 S R
4 EURL S-13.6 2 Meropenem MER = 0.12 0.5 S R
4 EURL S-13.6 Other phenotype Presumptive carbapenemase
4 EURL S-13.7 2 Temocillin TRM 32 64 S R
4 EURL S-13.8 1 Sulfamethoxazole SMX > 1024 > 1024 S R
6 EURL S-13.6 1 Cefotaxime FOT 1 0.5 R S
6 EURL S-13.6 2 Cefotaxime FOT 1 0.5 R S
6 EURL S-13.6 2 Cefoxitin FOX 16 8 R S
6 EURL S-13.6 2 Imipenem IMI 2 1 R S
12 EURL S-13.4 2 Ceftazidime TAZ 4 1 R S
17 EURL S-13.6 2 Imipenem IMI 2 1 R S
18 EURL S-13.3 1 Sulfamethoxazole SMX > 1024 32 R S
19 EURL S-13.1 2 Cefoxitin FOX 8 8 R S
19 EURL S-13.4 2 Cefoxitin FOX 4 4 R S
19 EURL S-13.6 2 Cefoxitin FOX 8 8 R S
19 EURL S-13.7 2 Ertapenem ETP = 0.12 0.06 R S
19 EURL S-13.8 2 Cefoxitin FOX 4 4 R S
22 EURL S-13.6 1 Cefotaxime FOT 2 0.5 R S
22 EURL S-13.6 2 Cefotaxime FOT 2 0.5 R S
22 EURL S-13.6 2 Cefoxitin FOX 16 8 R S
25 EURL S-13.6 2 Imipenem IMI 2 1 R S
26 EURL S-13.5 1 Colistin COL <= 1 4 S R
26 EURL S-13.6 1 Azithromycin AZI 16 32 S R
26 EURL S-13.6 2 Meropenem MER = 0.12 0.5 S R
26 EURL S-13.6 Other phenotype Presumptive carbapenemase
32 EURL S-13.3 1 Sulfamethoxazole SMX > 1024 32 R S
36 EURL S-13.6 2 Cefotaxime FOT 1 0.5 R S
37 EURL S-13.6 2 Imipenem IMI 2 1 R S
39 EURL S-13.5 1 Colistin COL 2 4 S R
39 EURL S-13.5 1 Trimethoprim TMP > 32 > 32 S R
39 EURL S-13.5 Presumptive ESBL No ESBL, AmpC- or carbapenemase
39 EURL S-13.6 1 Sulfamethoxazole SMX 1024 <= 8 R S
40 EURL S-13.4 1 Ampicillin AMP > 64 > 64 S R
40 EURL S-13.8 1 Trimethoprim TMP <= 0.25 > 32 S R
41 EURL S-13.6 2 Cefoxitin FOX 16 8 R S
41 EURL S-13.6 2 Imipenem IMI 2 1 R S
42 EURL S-13.6 1 Cefotaxime FOT 1 0.5 R S
42 EURL S-13.6 1 Meropenem MER = 0.12 0.5 S R
45 EURL S-13.5 1 Colistin COL 2 4 S R
59 EURL S-13.3 1 Sulfamethoxazole SMX > 1024 32 R S
59 EURL S-13.4 1 Ciprofloxacin CIP = 0.25 0.5 S R
60 EURL S-13.6 1 Cefotaxime FOT = 0.5 0.5 R S
64 EURL S-13.2 1 Chloramphenicol CHL 32 <= 8 R S
64 EURL S-13.4 No ESBL, AmpC- or carbapenemase Presumptive ESBL
64 EURL S-13.5 Other phenotype No ESBL, AmpC- or carbapenemase
64 EURL S-13.6 1 Meropenem MER = 0.12 0.5 S R
64 EURL S-13.6 No ESBL, AmpC- or carbapenemase Presumptive carbapenemase
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Deviations - Campylobacter
Lab no. Strain Antimicrobial Obtained MIC value
Expected 
MIC-value
Obtained 
interpretation
Expected 
interpretation
14 EURL C-13.1 Nalidixic acid NAL 2 64 S R
14 EURL C-13.1 Tetracycline TET <= 0.5 32 S R
14 EURL C-13.6 Nalidixic acid NAL 64 <=     1 R S
14 EURL C-13.6 Tetracycline TET 64 <=  0.5 R S
18 EURL C-13.3 Erythromycin ERY 16 4 R S
30 EURL C-13.2 Tetracycline TET 4 2 R S
32 EURL C-13.6 Ciprofloxacin CIP <= 0.12 8 S R
42 EURL C-13.3 Erythromycin ERY 16 4 R S
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Genotypic characterization (optional); genes detected in the ESBL-, AmpC, and carbapenemase producing Salmonella  strains
1 EURL S-13.1 CTX M-8 Whole genome sequenced
1 EURL S-13.2 TEM -1B Whole genome sequenced
1 EURL S-13.4 CTX M-9 Whole genome sequenced
1 EURL S-13.4 TEM -1B Whole genome sequenced
1 EURL S-13.6 OXA -48 Whole genome sequenced
1 EURL S-13.7 CTX M-15 Whole genome sequenced
1 EURL S-13.7 SHV -12 Whole genome sequenced
1 EURL S-13.8 CTX M-3 Whole genome sequenced
1 EURL S-13.8 TEM -1B Whole genome sequenced
2 EURL S-13.1 CTX M-8 Whole genome sequenced ResFinder 3.1
2 EURL S-13.4 CTX M-9 Whole genome sequenced ResFinder 3.1
2 EURL S-13.4 TEM -1B Whole genome sequenced ResFinder 3.1
2 EURL S-13.6 OXA -48 Whole genome sequenced ResFinder 3.1
2 EURL S-13.7 CTX M-15 Whole genome sequenced ResFinder 3.1
2 EURL S-13.7 SHV -12 Whole genome sequenced ResFinder 3.1
2 EURL S-13.8 CTX M-3 Whole genome sequenced ResFinder 3.1
2 EURL S-13.8 TEM -1B Whole genome sequenced ResFinder 3.1
9 EURL S-13.1 CTX M-8 PCR (published) JAC 2010;65;490-495
9 EURL S-13.4 CTX M-9 PCR (published) JAC 2010;65;490-495
9 EURL S-13.4 TEM -1 PCR (published) JAC 2010;65;490-495
9 EURL S-13.6 OXA -48 PCR (published) JAC 2010;65;490-495
9 EURL S-13.7 CTX M-15 PCR (published) JAC 2010;65;490-495
9 EURL S-13.7 SHV -12 PCR (published) JAC 2010;65;490-495
9 EURL S-13.8 CTX M-3 PCR (published) JAC 2010;65;490-495
9 EURL S-13.8 TEM -1 PCR (published) JAC 2010;65;490-495
17 EURL S-13.1 CTX M-8 Whole genome sequenced ResFinder 3.1
17 EURL S-13.2 TEM -1B Whole genome sequenced ResFinder 3.1
17 EURL S-13.4 CTX M-9 Whole genome sequenced ResFinder 3.1
17 EURL S-13.4 TEM -1B Whole genome sequenced ResFinder 3.1
17 EURL S-13.6 OXA -48 Whole genome sequenced ResFinder 3.1
17 EURL S-13.7 CTX M-15 Whole genome sequenced ResFinder 3.1
17 EURL S-13.7 SHV -12 Whole genome sequenced ResFinder 3.1
17 EURL S-13.8 CTX M-3 Whole genome sequenced ResFinder 3.1
17 EURL S-13.8 TEM -1B Whole genome sequenced ResFinder 3.1
20 EURL S-13.1 CTX M-8 Whole genome sequenced CTX-M-8 AF189721
20 EURL S-13.2 TEM -1B Whole genome sequenced bla TEM-1B AY458016
20 EURL S-13.4 CTX M-9 Whole genome sequenced CTX-M-9 AF174129
20 EURL S-13.4 TEM -1B Whole genome sequenced blaTEM-1B AY458016
20 EURL S-13.6 OXA -48 Whole genome sequenced bla OXA-48 AY236073
20 EURL S-13.7 CTX M-15 Whole genome sequenced bla CTX-M-15 AY044436
20 EURL S-13.7 SHV -12 Whole genome sequenced blaSHV-12 KF976405
20 EURL S-13.8 CTX M-3 Whole genome sequenced bla CTX-M-3 Y10278
20 EURL S-13.8 TEM -1B Whole genome sequenced blaTEM 1B AY458016
21 EURL S-13.4 CTX PCR (published)
Method Reference Primer 5 3 Primer 3 5Labno Strain Genetype Gene number
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Method Reference Primer 5 3 Primer 3 5Labno Strain Genetype Gene number
21 EURL S-13.6 OXA -48 PCR (published)
21 EURL S-13.7 CTX PCR (published)
21 EURL S-13.7 SHV PCR (published)
21 EURL S-13.8 CTX PCR (published)
22 EURL S-13.1 CTX Whole genome sequenced
22 EURL S-13.4 CTX Whole genome sequenced
22 EURL S-13.4 TEM Whole genome sequenced
22 EURL S-13.4 TEM PCR (published) Kim et al., 2009 AGT GCT GCC ATA ACC ATG AGT G CTG ACT CCC CGT CGT GTA GAT A
22 EURL S-13.5 CTX PCR (published) Kim et al., 2009 GAC AAA GAG AGT GCA ACG GAT G TCA GTG CGA TCC AGA CGA AA
22 EURL S-13.6 OXA Whole genome sequenced
22 EURL S-13.7 CTX Whole genome sequenced
22 EURL S-13.7 CTX PCR (published) Kim et al., 2009 TCC AGA ATA AGG AAT CCC ATG G TGC TTT ACC CAG CGT CAG AT
22 EURL S-13.7 SHV PCR (published) Kim et al., 2009 GAT GAA CGC TTT CCC ATG ATG CGC TGT TAT CGC TCA TGG TAA
22 EURL S-13.8 CTX Whole genome sequenced
22 EURL S-13.8 CTX PCR (published) Kim et al., 2009 TCC AGA ATA AGG AAT CCC ATG G TGC TTT ACC CAG CGT CAG AT
22 EURL S-13.8 TEM PCR (published) Kim et al., 2009 AGT GCT GCC ATA ACC ATG AGT G CTG ACT CCC CGT CGT GTA GAT A
25 EURL S-13.1 CTX M-8 PCR (in-house)
25 EURL S-13.4 CTX M-9 PCR (in-house)
25 EURL S-13.6 OXA -48 PCR (in-house)
25 EURL S-13.7 CTX M-15 PCR (in-house)
25 EURL S-13.7 SHV -12 PCR (in-house)
25 EURL S-13.8 CTX M-3 PCR (in-house)
25 EURL S-13.8 TEM -1B PCR (in-house)
32 EURL S-13.1 CTX M-8 PCR (published) PediatrInfectDisJ28:814-818
32 EURL S-13.1 DHA PCR (published)
32 EURL S-13.4 CTX M-9 PCR (published) PediatrInfectDisJ28:814-818
32 EURL S-13.4 TEM -1 PCR (published) AntimicrAgentsChemotherap2009
32 EURL S-13.6 OXA -48 PCR (published) J. Antimic.Chemothe(2009)
32 EURL S-13.7 SHV -12 PCR (published) FEMSMicrobiolLett1997152:1637
32 EURL S-13.8 TEM -1 PCR (published) AntimicrAgentsChemotherap2009
33 EURL S-13.1 CTX M-8 Whole genome sequenced M. Hunt et al. Ariba
33 EURL S-13.4 CTX M-9 Whole genome sequenced M. Hunt et al. Ariba
33 EURL S-13.4 TEM -1B Whole genome sequenced M. Hunt et al. Ariba
33 EURL S-13.6 OXA -48 Whole genome sequenced M. Hunt et al. Ariba
33 EURL S-13.7 CTX M-15 Whole genome sequenced M. Hunt et al. Ariba
33 EURL S-13.7 SHV -12 Whole genome sequenced M. Hunt et al. Ariba
33 EURL S-13.8 CTX M-3 Whole genome sequenced M. Hunt et al. Ariba
33 EURL S-13.8 TEM -1B Whole genome sequenced M. Hunt et al. Ariba
36 EURL S-13.1 CTX
PCR (published)
Hasman et al. beta-Lactamases among 
extendedspectrum beta-lactamase (ESBL)-resistant 
Salmonella from poultry, poultry products and human 
patients in The Netherlands. JAC 2005 Jul;56(1):115-21
ATGTGCAGYACCAGTAARGTKATGGC TGGGTRAARTARGTSACCAGAAYCAGCGG
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36 EURL S-13.4 CTX
PCR (published)
Hasman et al beta-Lactamases among extendedspectrum 
beta-lactamase (ESBL)-resistant Salmonella from poultry, 
poultry products and human patients in The Netherlands. 
JAC 2005 Jul;56(1):115-21
ATGTGCAGYACCAGTAARGTKATGGC TGGGTRAARTARGTSACCAGAAYCAGCGG
36 EURL S-13.6 OXA -48 PCR (published) Poirel et al. 2004. doi: 10.1128/AAC.48.1.15-22.2004 ttggtggcatcgattatcgg gagcacttcttttgtgatggc
36 EURL S-13.7 CTX M-15
PCR (published)
Hasman et al beta-Lactamases among extendedspectrum 
beta-lactamase (ESBL)-resistant Salmonella from poultry, 
poultry products and human patients in The Netherlands. 
JAC 2005 Jul;56(1):115-21
ATGTGCAGYACCAGTAARGTKATGGC TGGGTRAARTARGTSACCAGAAYCAGCGG
36 EURL S-13.7 SHV -12
PCR (published)
Briñas et al Beta-lactamases in ampicillinresistant 
Escherichia coli isolates from foods, humans, and healthy 
animals. AAC 2002 Oct;46(10):3156-63
CACTCAAGGATGTATTGTG TTAGCGTTGCCAGTGCTCG
36 EURL S-13.8 CTX M-15
PCR (published)
Hasman et al. beta-Lactamases among 
extendedspectrum beta-lactamase (ESBL)-resistant 
Salmonella from poultry, poultry products and human 
patients in The Netherlands. JAC 2005 Jul;56(1):115-21
ATGTGCAGYACCAGTAARGTKATGGC TGGGTRAARTARGTSACCAGAAYCAGCGG
58 EURL S-13.2 TEM PCR (published) EURL-AR method URL-AR primer - TEM-all URL-AR primer - TEM-all
58 EURL S-13.4 CTX PCR (published) EURL-AR method EURL-AR primer CTX-M9 EURL-AR primer CTX-M9
58 EURL S-13.4 CTX PCR (published) EURL-AR method EURL-AR primer - CTX M-all EURL-AR primer - CTX M-all
58 EURL S-13.4 TEM PCR (published) EURL-AR method EURL-AR primer TEM-all EURL-AR primer TEM-all
58 EURL S-13.6 OXA PCR (published) EURL-AR method EURL-AR primer - OXA-48 EURL-AR primer - OXA-48
58 EURL S-13.7 CTX PCR (published) EURL-AR method EURL-Ar primer - CTX M-all EURL-Ar primer - CTX M-all
58 EURL S-13.7 CTX PCR (published) EURL-AR method EURL-Ar primer - CTX-M1 EURL-Ar primer - CTX-M1
58 EURL S-13.7 SHV PCR (published) EURL-AR method EURL-Ar primer - SHV EURL-Ar primer - SHV
58 EURL S-13.8 CMY PCR (published) EURL-AR method EURL-AR primer - CMY-2 EURL-AR primer - CMY-2
58 EURL S-13.8 CTX PCR (published) EURL-AR method EURL-AR primer - CTX-M1 EURL-AR primer - CTX-M1
58 EURL S-13.8 TEM PCR (published) EURL-AR method EURL-AR primer - TEM-all EURL-AR primer - TEM-all
Legend: 
Fields shaded grey indicate that the gene was expected
Genes in bold and white font, were detected but not expected 
Note: TEM-1 does not confer ESBL-production and is as such not included as an expected result. TEM-1 or TEM-1B was, however, present in S-13.4 and S-13.8. As S-13.2 was not ESBL, AmpC or carbapenemase producing, submitted resu        
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17 EURL S-13.8 non ß-lactam resistance genes: aadA2, armA, aac(3)-lid, aac(6')-laa, mph(E), msr(E), sul1, dfrA12; 
TEM-1B: not ESBL
17 EURL S-13.7 non ß-lactam resistance genes: aph(6)-Id, aph(3'')-Ib, aac(6')-Iic, aac(6')-Iaa, catA2, sul1, tet(D), dfrA19
17 EURL S-13.6 non ß-lactam resistance genes: aac(6')-Iaa, mph(A); chromosomal point
17 EURL S-13.5 non ß-lactam resistance genes: mcr-4.6, aph(6)-Id, aac(6')-Iaa, sul2, dfrA
17 EURL S-13.4 non ß-lactam resistance genes: aac(6')-Iaa, tet(A); chromosomal point mutation gyrA p.S83; TEM-1B: not 
ESBL
17 EURL S-13.2 non ß-lactam resistance genes: aadA1, aac(6')-Iaa, mph(A), lnu(F); 
TEM-1B: not ESBL
17 EURL S-13.1 non ß-lactam resistance genes: aadA1, aac(6')-Iaa, sul2, tet(A)
20 EURL S-13.8 blaCTX-M-3 and blaTEM-1B identified using ResFinder
20 EURL S-13.7 blaCTX-M-15 and blaSHV-12 identified using ResFinder
20 EURL S-13.6 blaOXA-48 identified using ResFinder
20 EURL S-13.4 blaCTX-M-9 and blaTEM-1B identified using ResFinder
20 EURL S-13.2 blaTEM-1B identified using ResFinder- not an esbl
20 EURL S-13.1 CTX-M-8 detected through ResFinder
22 EURL S-13.8 Data analysis performed with ResFinder 3.1 data base.
22 EURL S-13.5 Data analysis performed with ResFinder 3.1 data base.
22 EURL S-13.7 Data analysis performed with ResFinder 3.1 data base.
22 EURL S-13.6 Data analysis performed with ResFinder 3.1 data base.
22 EURL S-13.1 Data analysis performed with ResFinder 3.1 data base.
22 EURL S-13.4 Data analysis performed with ResFinder 3.1 data base.
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